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CHAPTER I 
Introduction 
Cholesterol is a lipid molecule indispensable for the normal functioning of 
mammalian cells. It plays structural and functional roles in the cell membrane and 
functions as precursor for bile acids and steroid hormones. Other than this classic concept 
of cholesterol functions, it has been proposed that cholesterol plays an important role in 
protein and lipid trafficking, signal transduction, and generating cell surface polarity [1-
4].  For the normal execution of the above functions, the total cellular cholesterol level 
and distribution among the organelles and compartments of membrane is critical.  
Mammalian cells synthesize their own cholesterol endogenously and receive cholesterol 
exogenously through diet. The biosynthesis of the cholesterol molecule involves multiple 
steps and requires several enzymes. The exogenous influx of cholesterol is through 
lipoproteins, mainly low-density lipoproteins (LDL) via LDL receptor pathway [5, 6]. 
Cells also constantly efflux out excess cholesterol from organs. The synthesis, influx, 
efflux and distribution of cholesterol are tightly and precisely regulated. Several sterol 
response elements and transcriptional regulators such as liver-X-receptors (LXRs), 
retinoid- X-receptor (RXR), and peroxisome proliferators-activated receptor α,β, and γ 
(PPAR α,β,γ) take part to maintain the sterol balance in mammalian system. Numerous 
pathways exist to acquire cholesterol when it is required and efflux it when it is in 
abundance. Defects in the cholesterol metabolic and transport pathways result in 
numerous fatal disease conditions in humans and animals.  
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Excess of free cholesterol (FC) is toxic to cells [7]. The potential consequences of 
the toxicity induced by free cholesterol are loss of membrane fluidity, disruption of 
membrane domains, interruption of signal transduction, initiation of cell death, 
intracellular cholesterol crystallization, and formation of toxic sterols [7]. Cells prevent 
FC toxicity by FC efflux and acetyl-Coenzyme A acetyltransferase I (ACATI) mediated 
FC esterification [7]. Cholesterol efflux is indispensable to the cellular cholesterol 
homeostasis. Cholesterol ester hydrolase (CEH) reverses the FC esterification process. 
The synthesis and hydrolysis of cholesterol ester (CE) take place constantly in the cells 
and thus contribute significantly to FC efflux process  [8].  
Reverse cholesterol transport (RCT) is the process by which excess unesterified 
cholesterol is transported from peripheral tissues to the liver for excretion from the body 
[9, 10]. The FC efflux is one of the decisive early steps of the RCT and high-density 
lipoprotein (HDL) serves as the main acceptor for the cellular cholesterol released from 
the peripheral cells [11]. Apolipoprotein A-I (apoA-I) is the major protein component of 
HDL and plays important structural and functional roles. Human apoA-I is a 243-residue 
protein consisting of ten amphipathic helices synthesized primarily in the liver and the 
intestine [12]. Deficiency and naturally occurring mutations in apoA-I  fail to produce 
normal HDL levels and particles [13].  The plasma levels of HDL and apoA-I are 
inversely linked with the risk of cardiovascular diseases. Hence it is suggested that RCT 
is an important physiological process that protects against cardiovascular diseases [14].  
The rate of cellular cholesterol removal to apoA-I and HDL acceptors depends on 
multiple factors such as cholesterol abundance and organization in the plasma membrane 
[12-14], the content and nature of ATP-binding cassette transporter A1 (ABCAI) [14-17]   
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and scavenger receptor class B Type1 (SR-BI) receptors [12, 18, 19] and the nature and 
concentration of external sterol acceptors [20].  
Cholesterol Efflux Pathways 
There are at least five major pathways through which cholesterol is transported 
out of peripheral cells:(i) ABCAI mediates cholesterol and phospholipid transfer to lipid 
poor external acceptors like apoA-I, which is an early step in HDL formation [21] (Fig. 
1-1).  This is a unidirectional energy dependent pathway [22].  ATP-binding cassette 
(ABC) proteins consist of a large family of membrane receptors that transports a wide 
variety of substances including lipids, sterols, ions, peptides, proteins and drugs  across 
both intracellular and extracellular membranes [23, 24]. ABCAI conforms to the general 
architecture of the ABC transporters, consists of two sets of six trans-membrane domains 
and has two paired cytoplasmic Walker and an ABC signature motif [24]. Defects in 
ABCAI receptor cause Tangier disease, a condition described by increase in 
cardiovascular diseases due to accumulation of cholesterol in tissue macrophages and 
decreased HDL associated cholesterol in blood plasma [25]. ApoA-I is the major 
component of HDL in the circulation and evidence from several studies suggest that  
deficiency in ABCAI receptor or external acceptor apoA-I could seriously decrease the 
plasma HDL concentrations, which could  increase artherogenic risk. Even though 
several studies attempted to elucidate the mechanism of ABCAI mediated cholesterol 
efflux, it is still unclear and under intense debate. 
(ii) The HDL formed through ABCAI or other processes and other external 
acceptors can promote cholesterol efflux by acquiring cholesterol from the membranes 
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[12, 13] (Fig. 1-2).  This is a concentration dependent and passive process. One such 
passive process is the aqueous diffusion of cholesterol from cell surface onto external 
acceptors.  Another passive process, micorsolubilization, refers to the capability of 
apolipoproteins to acquire cholesterol and phospholipids independently of lipid 
transporters [26, 27].  
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Fig. 1. Cholesterol Efflux Pathways: 1. ABCA-I and apoA-I mediated FC and PL efflux. 2. Passive 
diffusion mediated FC and PL efflux. 3. SR-BI mediated lipid efflux. 4. ABCGI mediated lipid efflux. 5. 
Retroendocytosis mediated lipid efflux. 
 
(iii) The HDL can interact with SR-BI and efflux free cholesterol out of the cell 
and influx cholesterol ester in to the cells [18, 19] (Fig. 1-3). This process is energy 
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independent. SR-BI is a member of CD-36 family proteins, which contains two 
transmembrane domains and one large extracellular loop. Liver and steroidgenic cells are 
the major sites of SR-BI synthesis [18]. The ligands of SR-BI include, HDL, LDL, very 
low density lipoproteins (VLDL), reconstituted discoidal HDL (rHDL), other lipoproteins 
and large cholesterol ester rich spherical lipoproteins. The direction of lipid transfer is 
bidirectional.  Defects in SR-BI receptor reduced the clearance of HDL cholesterol from 
plasma in human and mice and this could lead to development of atherosclerosis [18]. 
(iv) ATP-binding cassette transporter GI (ABCGI) mediates cholesterol and 
phospholipids transfer to mature HDL molecules but not to lipid free apoA-I [28, 29] 
(Fig. 1-4). ABCGI is a half-transporter (one ATP binding site), which forms homodimers 
and the ABCGI mRNA is expressed ubiquitously among human tissues [30]. ABCGI 
gene silencing by RNA interference results in reduced efflux of cholesterol and 
phospholipids to mature HDL [31]. Overexpression of ABCGI protects liver, 
macrophages and several other tissues from massive lipid accumulation during high fat 
diet in murine models [31]. ABCGI also mediates the transport of cholesterol to LDL 
[32] . The data from several studies propose that ABCGI reorganizes and increases the 
availability of cholesterol enriched membrane domains for HDL molecules but not to 
apoA-I [33]. A direct HDL and ABCGI interaction is still under debate. Like the ABCAI 
lipid efflux, the mechanism of ABCGI lipid efflux is also under intense debate.  
(v) All of the above mechanisms suggest a direct and/or indirect interaction of 
lipoprotein to membrane receptors and or membrane lipids for cholesterol efflux. The cell 
surface event of direct and/or indirect interactions leads to transport of cholesterol and 
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phospholipids from internal locations to the plasma membrane (PM) and transferred to 
PM bound HDL or lipid free apolipoproteins. Several lines of evidence suggest an 
alternative model of cholesterol efflux mechanism where HDL and lipid free 
apolipoproteins are transported inside the cell via receptor-mediated endocytosis. The 
endocytosed lipoproteins remove cholesterol from intracellular locations, probably from 
lipid droplets and are resecreted without degradation (retroendocytosis) (Fig. 1-5). In 
1985, the first study in macrophages with gold labeled HDL and (125I) HDL suggested 
that HDLs bind to cell surface receptors and are internalized and transported to non-
lysososmal compartments. Finally, the HDL is secreted from the cells to tissue culture 
media without degradation [34]. Later the Schmitz et al in a different study suggested that 
the retroendocytosis process is damaged in tangier disease fibroblast, expressing a 
defective ABCAI receptor [35]. Since then several other studies suggested endocytosis 
and vesicular transport of HDL in different physiologically relevant cell lines [27, 36-39]. 
At present the HDL retroendocytosis is controversial. Shortly after the first paper on 
retroendocytosis of HDL, another study observed absence of internalization of (125I) HDL 
in fibroblast and macrophages [40]. Further more the authors suggested that HDL 
stimulate the transport of lipids from intercellular locations to cell surface, rather than 
undergoing retroendocytosis [40, 41]. 
  The retroendocytosis process was further tested in lipid free apoA-I. With a 
fluorescent labeled apoA-I and ABCAI-green fluorescent protein (GFP) fusion protein, 
the mechanism of ABCAI mediated efflux to apoA-I was studied in HeLa cells [42]. This 
ABCAI overexpression study suggested that ABCAI and apoA-I on the cell surface are 
internalized into early endosomes and can either recycle back to the plasma membrane or 
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traffic to late endocytic compartments. The apoA-I can collect lipids from late endocytic 
vesicles and traffic back to the PM and be released as the nascent HDL particle [42].  The 
apoA-I trafficking is an ABCAI dependent process [42].  Cyclosporin A is accepted as an 
inhibitor of ABCAI turnover in PM, but increases overall total expression of ABCAI in 
cells. This inhibitor considerably reduces the (125I) apoA-I uptake and re-secretion in 
macrophage cells [39]. Also several studies suggested that many classical endocytic 
proteins directly or indirectly linked with ABCAI. One such protein is RhoGTPase 
Cdc42 which interacts with ABCAI and modulates lipid efflux [27]. None of these 
studies suggested the mechanism of the receptor mediated retroendocytosis. The five 
pathways mentioned are separate and may function through different mechanisms. 
Mechanism of apoA-I and ABCA-1 mediated lipid efflux 
The in vitro and in vivo data from several studies suggest that ABCAI and lipid 
free apoA-I are critical for the biogenesis of pre β- HDL and lipid efflux from peripheral 
cells. As indicated previously, the mechanism of apoA-I and ABCAI mediated efflux is 
still not well understood, though extensively studied. At present three models have been 
proposed to explain the apoA-I and ABCAI mediated lipid efflux.  
The first model suggests that there is no direct interaction between apoA-I and 
ABCAI, but have spatial proximity between the protein and receptor ([43] Fig. 1-1B). 
ABCAI rearranges the lipid organization in plasma membrane, which increases the 
phosphatidylserine (PS) and enables apoA-I binding to phosphatidylserine in the 
exofacial side of the plasma membrane (PM). This study used a fluorescent labeled Cy5- 
apoA-I and ABCAI-green fluorescent protein (GFP) to determine apoA-I binding curves 
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and translational diffusion coefficients (D ) in membranes. The study concluded that 
saturation of surface binding of apoA-I to membrane does not correlate with the increase 
in ABCAI receptor (over expression) in the membrane and the translational diffusion 
coefficient (D ) of fluorescent Cy5-apoA-I correlates with molecular interaction with 
lipids rather than with a protein receptor. Later this report was challenged by Smith et al 
[44] by showing that ABCAI induction was coupled with a small increase in PM 
exofacial PS and the apoA-I is not competed by annexin V, a PS binding protein. Further 
more, with a photo-bleaching assay, the authors showed that Cy5- apoA-I does not 
rapidly diffuse in cell surface and speculated that apoA-I is directly or indirectly bound to 
an integral protein, probably with ABCAI [44]. 
In a different study, a variation of the above model was presented where ABCAI 
redistributes cholesterol to cell-surface sites, and it becomes available for removal by 
apolipoproteins. This study suggested a microsolubilization model of lipid efflux whereby 
apolipoproteins concurrently remove phospholipids and cholesterol from cell-surface 
domains formed by ABCAI [45]. 
The second model suggests a direct physical interaction between apoA-I and 
ABCAI at the cell surface and which is probably required for the lipid efflux facilitated 
by these two proteins [46] (Fig. 1-1). Several chemical cross-linking and 
immunoprecipitation studies concluded that apoA-I directly interact with ABCAI. The 
major drawbacks of these studies are failure in obtaining consistent stoichometery and 
binding affinity values for apoA-I and ABCAI interaction in increasing (up regulation) 
and decreasing (down regulation) receptor conditions and inability to give evidences to 
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suggest binding of apoA-I to ABCAI is a necessary step for lipid efflux. It is clear from 
the cross-linking studies that direct interaction between apoA-I and ABCAI is not 
sufficient for the movement of cholesterol out of the cell. 
The recent third model suggests a hybrid of first two models and consists of three 
steps.  In the first step, a small regulatory pool of apoA-I directly interacts with ABCAI 
(low affinity binding site) thereby increasing the transfer of phospholipids to exofacial 
surface of the plasma membrane. In the second step, the reorganized phospholipid in the 
outside surface creates membrane tension and is relieved by formation of exovesiculated 
lipid domains. The exovesiculated lipid domains formed promote high affinity binding of 
apoA-I (high affinity binding site) to these structures. In the third step, apoA-I 
spontaneously solubilizes the exovesiculated lipid domains to produce discoidal nascent 
HDL particle [47, 48]. The data from the above studies and several other studies were put 
together to create this more coherent hybrid model. But the authors failed to address the 
requirement and specificity of the very low amount of apoA-I binding directly to ABCAI. 
Also, the model suggested a spontaneous solubilization of lipid domains to produce   
discoidal nascent HDL particle, which should have produced an exponential lipid efflux 
kinetics at initial hours, which is not observed in several studies. 
Current Perspectives on Cholesterol efflux 
In the last decade considerable progress has been made in understanding the 
components of cholesterol efflux and HDL biogenesis. But the function and interactions 
of identified components of cholesterol efflux and mechanisms of the pathways are not 
well understood. There is no unique specificity for apoA-I in lipid efflux in different 
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cultured peripheral cells. The lipoproteins, apoA-I1, apo-III (insect lipoprotein), apoA-IV 
apoE, apoC and even an amphipathic peptide have efflux properties the similar to apoA-I 
in in vitro experiments. But the apoE-/- mutant and apoA-I -/-  apoE-/- double mutant 
studies in mice suggest that apoA-I is the key apolipoprotein that reduces  the 
accumulation of cholesterol from atherosclerotic lesions and skin, even in the presence of 
other lipoproteins in equal amounts [49-52]. The specific in vivo properties of apoA-I and 
the role of apoA-I in mediating cholesterol efflux in different peripheral tissues is not 
understood.   
ABCAI is expressed widely through out the mouse and human organs but the role 
and contribution of each organ in HDL biogenesis is not known. In the classical RCT 
model, the peripheral cells are the primary location for the prebeta-HDL biogenesis and 
ultimately transferred as mature HDL to the liver [9, 10]. Also, it has been suggested 
from ABCA-/- mutant mice studies that RCT is determined by different metabolic states 
in the peripheral organs and not by the concentration of plasma HDL and apoA-I [53]. 
But a recent study in chow fed ABCAI-/- liver mutant mice challenges the classical RCT 
model and proposed that the liver is the single most significant source of plasma HDL 
(82%), where pre- β HDL is synthesized [54]. Another study with ABCA-/- intestine 
mutant suggests that intestine also plays a significant role in the biogenesis of HDL 
(30%) through ABCAI receptor [55]. These studies were conducted by specifically 
mutating the liver and intestine ABCAI. But the studies on the total peripheral cholesterol 
efflux contribution per day per kg of body weight in mice suggest an opposing view to 
the above 2 studies [56]. There is significant contribution of cholesterol efflux from 
peripheral cells.  Considering the complexities and cross talk involved between pathways 
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and tissue secretory components, these specific mutation studies are not sufficient to 
conclude the contribution of peripheral cells in the HDL biogenesis and total RCT. Even 
though muscle, adipose tissue, skin and other peripheral tissues express comparable or 
elevated amounts of cholesterol and ABCAI as of liver and intestine, their significance in 
the contribution of lipid efflux by HDL biogenesis and maturation is undermined by the 
above studies. The tissue that contributes the greatest mass of cholesterol to the RCT 
process is till unknown 
As explained earlier there are several cholesterol efflux pathways. The relative 
contribution of lipid efflux by different pathways and components is not known. Recent 
study in cultured macrophages in the serum environment with ABCAI and SR-BI 
receptor inhibitors, it has been suggested that the contribution of these receptors in 
mediating cholesterol efflux is low (<30%) compared to the background efflux (>70%) 
[57]. A large percentage of efflux is not mediated by these receptors in the presence of 
serum lipoproteins. It is possible that there are other uncharacterized receptors/proteins 
and pathways involved in the cholesterol/lipid efflux process.  
Adipose Tissue 
Adipose tissue is a complex organ involved in synchronizing a variety of 
biological processes including energy metabolism, neuroendocrine , and immune 
function [58-61]. Adipose tissue is a major secretory organ and the secretory products 
communicate locally and with other organs like liver, brain and skeletal muscles [62]. 
The cross- talk between the secretory products and other organs are very important for 
the normal energy homeostasis of the body and a disturbance in the balance of the 
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secreted products will result in several disease conditions like insulin resistance leading 
to type 2 diabetes, heart diseases, and stroke (metabolic syndrome) [62].  Leptin, 
Adiponectin, resistin, lipoprotein lipase, acylation stimulating protein, fast-induced 
adipose factor, visfatin and vaspin are the few studied among hundreds of secretory 
adipokines of adipose tissue which are important for the normal energy metabolism. 
Human adipose tissue consists of various types of cells that include mature adipocyes 
(50-70%), preadipocytes (20-40%), endothelial cells (1-10%), macrophages (10-30%) 
and other cells (unknown percentage) [63]. The percentage cell composition of adipose 
tissue fluctuates according to different fat depot locations, metabolic state and disease 
conditions [63]. It has been demonstrated that the macrophages get attracted more during 
increasing fat accumulation in body  and a significant amount of protein expressed in 
adipose tissue has macrophage characteristics [63]. Obese animals express high levels of 
inflammatory proteins like TNF-alpha, IL-6, IL-8, IL-18, MIF, and IL-1Beta , which are 
the key initiation factors for the development of metabolic syndrome. The increased 
secretion of these inflammatory proteins by adipose tissue are possibly due to the 
increasing macrophage accumulation in adipose tissue [63]. Metabolic syndrome is now 
suggested as a state of impaired function of the secretory products of adipose tissue and 
associated cells. These findings and speculations underline the prerequisite of further 
extensive study of adipose tissue metabolism.  
Whole body energy metabolism is regulated by adipose tissue through its stored 
lipids; modulated by intrinsic and extrinsic signals. The stored lipids in adipose tissue are 
in a specialized organelle called lipid droplets (LD), which are formed by a monolayer of 
phospholipids and sterols surrounding a hydrophobic core of neutral lipids, mainly 
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consisting of triacylglycerol (TAG), and sterol esters. Adipose tissue constitutes one of 
the largest reservoirs of cholesterol in vertebrates [61]. The size of the cholesterol pool in 
adipose tissue is dependent on the mass of adipose tissue and, thus, proportional to the 
cellular triglyceride (TG) content [64, 65]. As in several other cell types, most of the 
cellular cholesterol of adipocytes resides in the plasma membrane and the lipid droplets. 
The lipid droplets found in tissues such as liver, adrenal glands, and enterocytes contain 
cholesterol, mostly, in the form of cholesterol esters. However, in adipocytes most of the 
lipid-droplet cholesterol is found in the non-esterified form [65, 66].  
The cholesterol content of peripheral cells such as adipose tissue is controlled 
through the balance between uptake, release, synthesis, and catabolism of cholesterol 
[67]. Because the capacity of cholesterol synthesis and catabolism of adipocytes is very 
low [64, 66], the cholesterol content of adipose tissue is dependent on the balance 
between efflux and influx of cholesterol. Therefore, the rate of efflux to extracellular 
cholesterol acceptors could affect the cholesterol content of adipose tissue to a higher 
extent than in other tissues, such as liver, which have an active cholesterol metabolism. 
Maintenance of the cholesterol balance of adipose tissue is likely to be important to the 
proper metabolic functioning of the tissue [68, 69]. Moreover, since adipose tissue 
contains one of the largest pools of free cholesterol, the output of free cholesterol from 
this peripheral tissue might affect the homeostasis of cholesterol metabolism, in general.  
Cholesterol Efflux in Adipose Tissue 
The dynamic role of adipose tissue in energy balance through its ability to 
accumulate (Lipogenesis; deposition of lipids) or release (Lipolysis; hydrolysis of 
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triacylglycerol) fatty acids, and the fact that there is a correlation between the TG and 
cholesterol contents of adipocytes suggests that the metabolism of these two lipids could 
be coupled. Because both TG and cholesterol are mostly confined to the lipid droplet, the 
changes in TG content that normally occur in adipocytes, for instance after fasting or 
intense physical activity [64, 67, 68], could be accompanied by changes in the rate of 
cholesterol efflux to external acceptors. Although there is scarce specific information 
about the possible role of the metabolic state of adipocytes on the rate of cellular 
cholesterol efflux, studies showing that differentiation of pre-adipocytes [69] and 
development of obesity[70] are associated to changes in the cholesterol content of 
adipocytes membranes suggest that changes in the metabolism of TG could affect the 
transport of cholesterol.  
Previous studies have shown that adipocytes release cellular cholesterol to HDL 
[71, 72] and apoA-I [71, 73-76]. The effect of break down of TG on the rate of cellular 
cholesterol efflux from adipocytes to apoA-I or HDL and the efflux mechanism involved 
are not  well studied  in adipose tissue. However, as is the case for most tissues, the 
pathways and mechanisms involved in cholesterol efflux in adipose tissue, and their 
relative contribution to the overall efflux process and RCT, have not been fully 
established.  
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CHAPTER II 
Stimulation of lipolysis enhances the rate of cholesterol efflux 
to HDL in adipocytes 
 
Introduction 
Adipose tissue constitutes one of the largest reservoirs of cholesterol in 
vertebrates [61].The size of the cholesterol pool in adipose tissue is dependent on the 
mass of adipose tissue and, thus, proportional to the cellular triglyceride (TG) content 
[64, 65]. As in several other cell types, most of the cellular cholesterol of adipocytes 
resides in the plasma membrane and lipid droplets. The lipid droplets found in tissues 
such as liver, adrenal glands, and enterocytes contain cholesterol, mostly, in the form of 
cholesterol esters. However, in adipocytes most of the lipid droplet cholesterol is found in 
the non-esterified form [65, 66]. The cholesterol content of peripheral cells is controlled 
through the balance between uptake, release, synthesis, and catabolism of cholesterol 
[77]. Because the capacity of cholesterol synthesis and catabolism of adipocytes is very 
low [64, 66], the cholesterol content of adipose tissue is dependent on the balance 
between efflux and influx of cholesterol. Therefore, the rate of efflux to extracellular 
cholesterol acceptors could affect the cholesterol content of adipose tissue to a higher 
extent than in other tissues, such as liver, which have an active cholesterol metabolism. 
Maintenance of the cholesterol balance of adipose tissue is likely to be important to the 
proper metabolic functioning of the tissue [73, 78]. Moreover, since adipose tissue 
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contains one of the largest pools of free cholesterol, the output of free cholesterol from 
this peripheral tissue might affect the homeostasis of cholesterol metabolism, in general. 
High density lipoprotein (HDL) plays a major role in the removal of cholesterol from 
peripheral tissues [11]. The rate of cellular cholesterol removal to HDL depends on 
multiple factors, such as the cholesterol abundance in plasma membrane [12, 13] the 
function of ABCAI [79, 80] and SR-BI receptors [12, 18-20] , and the nature and 
concentration of external sterol acceptors [20]. As is the case for other tissues, the 
mechanisms involved in cholesterol efflux in adipose tissue, and their relative 
contribution to the overall efflux process, have not been fully established. 
The dynamic role of adipose tissue in energy balance through its ability to 
accumulate or release fatty acids, and the fact that there is a correlation between the TG 
and cholesterol contents of adipocytes suggests that the metabolism of these two lipids 
could be coupled. Because both TG and cholesterol are mostly confined to the lipid 
droplet, the changes in TG content that normally occur in adipocytes could be 
accompanied by changes in the rate of cholesterol efflux to external acceptors. For 
instance, an increase in plasma cholesterol levels has been observed after fasting or 
intense physical activity, [67-69]. Although there is scarce specific information about the 
possible role of the metabolic state of adipocytes on the rate of cellular cholesterol efflux, 
studies showing that differentiation of pre-adipocytes [69] and development of obesity 
[70] are associated to changes in the cholesterol content of adipocyte membranes suggest 
that changes in the metabolism of TG could affect the transport of cholesterol. Previous 
studies have shown that adipocytes release cellular cholesterol to HDL [71, 72]. 
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 The purpose of the current study was to examine the effect of lipolysis on the rate of 
cellular cholesterol efflux from 3T3 L1 adipocytes to discoidal reconstituted HDL. 
 
Experimental Procedures 
Materials. 3T3 L-1 cells were purchased from American Type Cell Culture 
(Manassas, VA). Polyclonal anti-ABCAI antibody was obtained from Novus-Biologicals 
(Littleton, CO). Monoclonal antibody for plasma membrane Na+K+-ATPase was 
purchased from the 
Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA). 
Horseradish peroxidase (HRP) tagged antibodies were purchased from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA). Fatty acid free bovine serum albumin, protease 
inhibitors (phenyl-methyl sulfonyl fluoride, leupeptin, aprotinin, antipain), isobutyl 
methyl xanthine (IBMX), dexamethasone, trypsin, biotin, sodium pyruvate, insulin, 
streptomycin and penicillin were purchased from Sigma Chemicals Co. (St. Louis, MO). 
Fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT). Dulbecco’s modified 
Eagle’s medium (DMEM) was purchased from Cellgro Mediatech, Inc (Herndon, VA). 
[3H]-Cholesterol (60 Ci/mmoL) was from Perkin-Elmer (Waltham, Massachusetts). 
Chemiluminiscence kit for Western blots was obtained from Amersham Biosciences 
(Piscataway, NJ). 
 
Cell Culture. 3T3 L-1 pre-adipocytes were cultured at 370C in 8% CO2 
atmosphere in high glucose DMEM supplemented with 10% FBS and 0.01% 
streptomycin and penicillin antibiotics. One day after confluence, the differentiation into 
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adipocytes was induced by addition of IBMX (111 µg/mL), dexamethasone (0.46 µg 
/ml), and insulin (1.5 µg /ml) in the medium that was also supplemented with biotin (4 
µg/ml) and sodium pyruvate (100 µg /ml) [81]. After 48 h, the cells were incubated in 
DMEM/10 % FBS containing insulin, biotin, and sodium pyruvate for additional 48 h. 
Afterwards, the cells were maintained in DMEM/10% FBS. All experiments were 
conducted 12 days after completion of the differentiation period. 
 
Preparation of Reconstituted Discoidal HDL Particles. Liposomes were 
obtained by dispersing a thin film of dimyristoyl-phosphatidylcholine (DMPC) in PBS 
buffer, pH 7.5 [82]. ApoA-I was purified from human plasma and kept in 2 M guanidine 
hydrochloride at -200C [83]. A dialyzed aliquot of apoA-I in PBS buffer pH 7.5 was 
added to the DMPC vesicles at a lipid:protein ratio of 1:1 (w/w) and incubated at 240 C 
for 12 h. Samples of the reconstituted HDL particles (rHDL) were analyzed by gel 
filtration-FPLC using a Superose 6 column (Pharmacia, Piscataway, NJ) and 
nondenaturing gradient gel electrophoresis as described [82]. 
 
Cholesterol Efflux. Adipocytes cultured in twelve well dishes were radiolabeled 
by incubation for 24 h with [3H]-cholesterol (2 µCi/ml) in DMEM containing 2.5% FBS. 
The media was removed and the cells were incubated for 3 hours in serum-free DMEM 
containing 0.2% BSA (DMEM/BSA) and, before the beginning of the experiment, rinsed 
twice with DMEM/BSA. The experiments were started by addition of fresh DMEM/BSA 
(basal lipolysis) or DMEM/BSA supplemented with 1µg/ml of isoproterenol (high 
lipolysis). Cholesterol efflux to rHDL was determined at 370 C in the corresponding, 
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basal or high lipolysis media containing HDL at a concentration of 50 µg of apoA-I/ml. 
Background cholesterol efflux was determined in the corresponding basal and high 
lipolysis media containing no acceptors. Microliter aliquots of the medium were collected 
at specific time intervals to estimate the fraction of [3H]-cholesterol released into the 
medium by scintillation counting. At the end of the incubation, the cells were washed 
with phosphate buffered saline (PBS) twice and the lipids extracted with 2-propanol [84]. 
The lipid extract was used to determine the fraction of radiolabeled cholesterol remaining 
in the cells. Cholesterol efflux was expressed as the percentage of radiolabeled 
cholesterol released into the media as: 100x [3H]-Cholesterol in media /([3H]-Cholesterol 
in media + [3H]-Cholesterol in cells). The effect of BFA on cholesterol efflux was studied 
by addition of BFA to the DMEM/BSA medium at a final concentration of 10 µg /ml.  
 
Ultracentrifugation. Samples of medium were fractionated by ultracentrifugation 
in a KBr density gradient as previously reported [82]. Aliquots of the fractions were used 
to determine [3H]-cholesterol radioactivity. The density of the fractions was determined 
by refractometry. The subcellular distribution of [3H]-cholesterol is determined by 
discontinuous sucrose gradient centrifugation of homogenates of 3T3L-1 cells. After the 
corresponding treatment, the cells were washed with PBS and harvested by scrapping in 
cold 10 mM Tris-HCl buffer pH 7.4 containing 0.25 M sucrose, 1 mM EDTA, and 
protease inhibitors. A cell homogenate was prepared with a tight fitting Dounce 
homogenizer. The homogenate was adjusted to 50% sucrose, then 5.0mL each of 40%, 
30%, 20%, 10% and homogenization buffer without sucrose was layered on top of the 
gradient. After centrifugation in SW28 rotor at 23,000 RPM for 18 h the gradient was 
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fractionated in equal volumes and an aliquot of the fractions were scintillation counted to 
determine the radioactivity. 
 
Lipolysis. The extent of lipolysis was estimated from the fatty acids released into 
the cell medium. Fatty acids were determined spectrophotometrically using the enzyme 
coupled assay NEFA B,Wako (Richmond, VA ) . 
 
Isolation of Plasma Membrane (PM). After the corresponding treatment, the 
cells were washed with PBS and harvested by scrapping in cold 10 mM Tris-HCl buffer 
pH 7.4 containing 0.25 M sucrose, 1 mM EDTA, and protease inhibitors. A cell 
homogenate was prepared with a tightfitting Dounce homogenizer. Plasma membranes 
were isolated from the homogenate using the fractionation procedure previously 
described [85]. The homogenate was centrifuged at 19,000g for 20 min. The pellet 
obtained from this centrifugation was resuspended in 0.25 M sucrose/10 mM Tris-HCl 
buffer, layered onto a discontinuous sucrose gradient, 0.75 and 1.12 M sucrose, and 
centrifuged at 100,000g in a SW40 rotor for 75 min. The band at the interphase of the 
0.75 M and 1.12 M sucrose layers (plasma membrane) was collected, diluted with 50 mM 
Tris-HCl buffer pH 7.4, and centrifuged at 40,000g for 30 min.  
 
Western Blot Analysis. Aliquots of the membrane preparations containing 15 µg 
of protein were mixed with reducing SDS-sample buffer and subjected to SDS-PAGE in 
8% acrylamide: bisacrylamide gels. The proteins were transferred to a nitrocellulose 
membrane and probed with a rabbit anti-mouse/human ABCAI (1:750 dilution), and anti- 
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SR-BI (1:1000). Parallel Western blots were run to determine the abundance of Na+/K+ 
ATPase using a monoclonal anti-Na+/K+ ATPase antibody (1:10 dilution). All secondary 
antibodies were used at a 2500-fold dilution. The bands were visualized by 
chemiluminescence and quantified by densitometry. 
 
Lipid Analysis. Cholesterol contents of plasma membrane fractions were 
determined spectrophotometrically using the enzyme coupled assay Infinity™ 
Cholesterol (Thermo Electron Corporation). The cholesterol data were normalized for 
protein content. Protein contents were determined using the bicinchoninic acid method 
(Micro BCA Protein Assay Reagent Kit, Pierce Biotechnology). 
 
Fluorescence Anisotropy. Fluorescence anisotropy measurements were 
performed at 24 0C in a K2 spectrofluorometer (ISS, Urbana, IL) as previously described 
[86]. Plasma membrane samples, 1 ml containing 50 µg/ml of protein, were incubated 
with 0.75 nmoles of DPH (1, 6- diphenyl-1, 3, 5-hexatriene) for 30 min. Sample 
temperature was controlled with a circulating water bath. Emission intensities were 
measured at 431 nm with excitation at 355 nm. Steadystate fluorescence anisotropy, r, 
was calculated as: r = (Ivv- G Ivh) / (Ivv + 2GIvh) 
IVV and IVH are the parallel and perpendicular polarized fluorescence intensities measured 
with vertically polarized excitation light. The intensities were corrected for scattering 
using unlabeled samples. Instrumental polarization selectivity was corrected by means of 
the G factor, which is calculated from the ratio of parallel and perpendicular intensities 
determined with horizontally polarized excitation light. 
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Statistical Analysis. The statistical significance of the data was evaluated with the 
paired Student’s t-test using the program Instat (Graphpad). 
 
Results 
Cellular cholesterol efflux to rHDL. The rate of cholesterol efflux to rHDL was 
studied in adipocytes that were prelabeled with [3H]-cholesterol for 24 h. Under these 
conditions 96% of the radiolabeled cholesterol is found as such, and the remaining 4% is 
found as cholesterol esters (data not shown). This distribution of radiolabeled cholesterol 
is nearly identical to the relative mass contents of cholesterol and cholesterol ester 
previously reported for adipocytes [65, 66, 73] suggesting that in 24 h the incorporated 
radiolabeled cholesterol reaches a physiological distribution. The subcellular distribution 
of [3H]- cholesterol was determined by sucrose  gradient centrifugation of homogenates 
of 3T3L-1 cells (Fig. 2A). The [3H]- cholesterol distribution profile shows that the lipid 
droplet is the major location of cellular cholesterol (approximately 60% ). 
 
To study cholesterol efflux HDL particles (rHDL) were reconstituted using 
human apoAI and phosphatidylcholine at a 1:40 molar ratio. Using this molar ratio the 
lipoproteins obtained are highly homogeneous. Analysis of the lipoproteins obtained by 
nondenaturing gradient gel electrophoresis shows a single major band with an apparent 
diameter of ~7.8 nm (Figure 2B). Figure 2C shows that HDL promotes [3H]-cholesterol 
efflux from adipocytes in a dose dependent manner. At the maximum concentration of 
lipoprotein tested (100 µg apoA-I/ml), and after five hours of incubation, HDL promotes 
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the release of approximately 14% of the total cellular cholesterol. A representative time 
course of cholesterol efflux from adipocytes to HDL (50 µg/ml) is shown in Figure 2D. 
 
Figure 2E shows the density distribution of the radiolabeled cholesterol found in the cell 
medium after incubation of [3H]-cholesterol pre-labeled adipocytes in DMEM containing 
HDL. The profile of cholesterol distribution was obtained by ultracentrifugation of the 
medium in a density gradient of KBr. The position of the maximum of radioactivity in the 
density gradient (density~ 1.11 g/cm3) is consistent with the association of the cholesterol 
released by the cells with HDL. Figure 2F shows the change in the subcellular 
distribution of [3H]- cholesterol in the presence of  the external acceptor, HDL in 3T3L-1 
cells. The distribution profile of the subcellular [3H]-cholesterol was obtained by 
ultracentrifugation of cell homogenate on a discontinuous sucrose gradient for 18 h. The 
profile of [3H]-cholesterol suggests that HDL receives cholesterol from lipid droplets and 
membranes. 
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Fig. 2. Cellular Cholesterol Efflux from Adipocytes to Discoidal HDL. A) Distribution of the [3H]- 
cholesterol in fractions from the sucrose gradient centrifugation of an homogenate of 3T3L-1 cells B) 
HDL-dose response: [3H]- cholesterol pre-labeled adipocytes were incubated for 5 h at 370C in DMEM 
containing different concentrations of rHDL; C) Non denaturing gel electrophoresis of the reconstituted 
HDL particles used in the studies. The lipoprotein (lane 1) and size markers (lane 2) were stained with 
Coomassie Blue; D) Time course of cholesterol efflux: adipocytes were incubated in DMEM medium 
containing HDL (50 µg apoA-I/ml). Samples from three wells were taken at different time points. 
Following the incubation, the cellular lipids and cell culture media were analyzed for radioactivity. The 
cholesterol efflux data were corrected for the radiolabeled cholesterol released in the absence of HDL. Data 
represent the percent of cellular cholesterol released in the presence of HDL (average values +/- S.E). Data 
are from six wells for the HDL dose response and three wells for the time course experiment; E) DMEM-
medium containing HDL was collected after incubation for 5 h with [3H]-cholesterol pre-labeled 
adipocytes. The medium was subjected to ultracentrifugation in KBr density gradient. Aliquots of the 
density gradient were used for radioactivity and density determination. F) Distribution of the [3H]- 
cholesterol in fractions from the gradient centrifugation of an homogenate of 3T3L-1 cells incubated in the 
presence and absence of external acceptor rHDL. 
 
 
Effect of lipolysis on the rate of cholesterol efflux to rHDL. 
 To examine the effect of lipolysis on cholesterol efflux, [3H]-cholesterol 
prelabeled cells were incubated in DMEM/BSA in the absence or in the presence of the 
non-specific β-adrenergic agonist, isoproterenol. In the presence of isoproterenol, the rate 
of lipolysis, as estimated from the fatty acid (FA) released into the incubation media, 
increases ~7-8 fold, from ~3.2 to ~27 nmol FA/mg of cellular protein.h. The effect of 
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lipolysis on the efflux of cholesterol from adipocytes to discoidal HDL is shown in 
Figure 3. After 180 min incubation with rHDL, the average extent of cholesterol efflux in 
adipocytes with basal lipolytic activity was 8.06 +/- 0.38% and increased to 9.99 +/- 
0.32%, when lipolysis was activated. A similar conclusion was obtained comparing the 
efflux data obtained at 300 min. At both time points, activation of lipolysis promotes a 
significant increase in the extent of cholesterol efflux to discoidal HDL, 23.8% increase 
at 180 min, P<0.001, and 22.3% at 300 min, P<0.0001. 
 
 
Fig. 3. Effect of Lipolysis on the of Rate Cellular Cholesterol Efflux to HDL. Adipocytes were labeled 
with [3H]-cholesterol as indicated in experimental procedures and incubated in DMEM containing rHDL 
(50 µg apoA-I/ml) for 180 min or 300min, at 370 C. “High lipolysis” and “Basal Lipolysis” refer to cells 
incubated in the medium with or without isoproterenol, respectively. Cholesterol efflux is represented as 
percentage of the total cellular cholesterol as indicated in methods. The data plotted were corrected for the 
radiolabeled cholesterol released in the absence of HDL and represents the average values +/- the S.E. of 9 
experiments for 180 min and 10 experiments for 300 min. Student’s t-test analysis indicated significant 
differences between the mean values of cholesterol efflux (high vs basal lipolysis) at both 180 min 
(P<0.001) and 300min (P < 0.0001). 
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Activation of lipolysis promotes a decrease in the cholesterol content of plasma 
membranes. 
To study a possible role of the cholesterol content of the plasma membranes in the 
enhancement of cholesterol efflux induced by activation of lipolysis, plasma membranes 
of [3H]-cholesterol labeled adipocytes were isolated from cells incubated in DMEM 
medium in the absence of HDL after a five hour period of incubation in the absence or in 
the presence of isoproterenol. The isolated membranes were analyzed for protein and 
radiolabeled cholesterol content (cpm). As shown in the Figure 4A, activation of  
lipolysis promotes a decrease in the content of radiolabeled cholesterol of the plasma 
membrane. Nearly identical changes are observed when membranes are isolated from 
adipocytes incubated for periods of 1 or 3 hours (data not shown). The decrease in 
cholesterol content of the plasma membrane is accompanied by an increase in the 
cholesterol content of the lipid droplets (data not show). Given the fact that changes in 
cholesterol content usually affect the mobility and/or packing of the lipid molecules in 
the bilayer [87], possible changes in the physical properties of the plasma membranes 
were investigated by determining the fluorescence anisotropy of DPH. Figure 4B shows 
that activation of lipolysis promotes a significant decrease in the fluorescence anisotropy 
of DPH from 0.154 +/- 0.005 to 0.141 +/- 0.004. The lower fluorescence anisotropy of 
DPH in membranes isolated from cells with high lipolytic activity is consistent with the 
observed decrease in cholesterol content of the membranes. 
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Fig. 4. Effect of Lipolysis on the Cholesterol Content of Plasma Membrane of Adipocytes. [3H]-
Cholesterol pre-labeled cells were incubated in 75 cm2 tissue culture flasks for 5 h in DMEM media. The 
media of samples labeled “High Lipolysis” contained isoproterenol. After incubation, the cells were 
homogenized, and plasma membranes isolated as described in methods. Panel A shows the ratios of 
radiolabeled cholesterol to protein content observed in the membranes. Bars represent the mean values of 
two membrane preparations +/- the difference. Panel B shows the data of anisotropy of fluorescence of 
DPH obtained in membrane preparations isolated from cells with basal and high lipolytic activity. 
Triplicate samples containing 50 µg/ml of protein were incubated with DPH at a molar ratio of 100:1 
(phospholipid to DPH) for 30 min. Fluorescence anisotropy (mean +/- SD) was determined at 240C. 
 
Effect of lipolysis on ABCAI and SR-BI levels in plasma membrane. 
A possible role of the cholesterol transporters ABCAI and SR-BI in the 
enhancement of cholesterol efflux was evaluated by studying the protein levels of the 
transporters in plasma membrane isolated form adipocytes under basal and activated 
lipolytic conditions. Plasma membranes were isolated from the cell monolayer by 
ultracentrifugation in a sucrose gradient. The isolated fraction floated at the interface 
between the 0.75 M and 1.12 M sucrose and, compared to the cell homogenate, was 
highly enriched in Na+/K+ ATPase. Western blotting of plasma membrane proteins with a 
polyclonal ABCAI antibody showed no changes in the level of ABCAI protein after a 
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sustained five hour activation of the lipolysis (Fig. 5A). In contrast some experiments, we 
observed a slight decrease in the level of ABCAI protein in plasma membrane. 
Furthermore, no changes in the membrane levels of ABCAI were observed when the cells 
were incubated in the presence of apoA-I or rHDL. Western blotting of plasma 
membrane proteins isolated from control, or isoproterenol treated, cells with a polyclonal 
SR-BI antibody did not reveal a lipolysis related variation in SRB1 content, either (Fig. 
5A). Overall, the results suggest that the observed increase in cholesterol efflux during 
lipolytic activation is not related to increases in the plasma membrane levels of ABCAI 
or SR-BI. 
 
Fig. 5. Effect of Lipolysis on ABCAI and SR-BI Protein Contents. A) Western blotting of ABCAI, 
Na+/K+ ATPase and SR-BI receptor was performed in plasma membrane samples (15 µg of potein/sample) 
after SDS-PAGE, as described in experimental procedures. B) Coomassie blue stained SDS-PAGE of 
plasma membrane proteins (15 µg). Membrane samples were isolated from adipocytes incubated 300 min 
in DMEM (samples labeled “C”) or in DMEM containing isoproterenol (samples labeled “I”). 
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Effect of Brefeldin A on the enhancement of cholesterol efflux to rHDL.  
The lack of correlation between the cholesterol content of plasma membrane and 
the rate of  cholesterol efflux suggested that changes in the dynamics of intracellular 
transport of lipids could be involved in the induction of cholesterol efflux associated to 
activation of the lipolysis. To investigate this possibility the efflux of cellular cholesterol 
was studied in the presence and in the absence of Brefeldin A, which is known to alter 
vesicular lipid and protein transport by promoting fusion of Golgi and endoplasmic 
reticulum compartments [88, 89]. Under basal lipolytic conditions Brefeldin A promoted 
a minor, not significant, decrease in cholesterol efflux to HDL (Fig. 6), 6% (P<0.1). On 
the other hand, when lipolysis is activated, BFA reduces the enhancement of cholesterol 
efflux to HDL to the level observed in cells with basal lipolytic activity (Fig. 6). Thus, 
when lipolysis is activated, Brefeldin A promotes a decrease in the extent of cholesterol 
efflux, from 11.52 +/-0.55 to 9.69 +/- 0.22 % (P<0.01). 
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Fig. 6. Effect of Brefeldin A on the Rate of Cholesterol Efflux to rHDL. 3T3L-1 adipocytes were 
incubated for 5 h in DMEM with, or without, Brefeldin A at 10 µg/ml. HDL was used at a concentration of 
50 µg of protein/ml.  Lipolysis was activated by incubating the cells in media containing isoproterenol. 
Each bar represents the mean values (%) +/- the standard error of cellular cholesterol efflux of three 
experiments. Comparison of the means through the t-test rendered P-values of 0.057 for the effect of BFA 
under basal lipolysis, and 0.0062 for the effect of BFA under high lipolysis. 
 
 
DISCUSSION 
The investigation of the effect of the lipolytic state on adipocytes on the rate of 
cellular cholesterol efflux is of interest because, due to its large content of unesterified 
cholesterol, adipose tissue could play a major role in the homeostasis of cholesterol 
metabolism and transport. The relative cholesterol content of adipose tissue varies with 
the degree of obesity of the individual. However, adipose tissue always represents a 
major reservoir of cholesterol and in cases of major obesity it may contain over 50% of 
the total body cholesterol [90]. The present study shows that activation of the lipolysis is 
associated to an increase in adipocyte cholesterol efflux to HDL. These findings suggest 
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the existence of a metabolic link between cellular transport of cholesterol and the 
lipolytic activity of adipose tissue. This metabolic link argues against the view of adipose 
tissue as a passive cholesterol buffering sink. The increase in efflux associated to 
lipolysis could be partially responsible of the increase in plasma cholesterol that is 
observed after long periods of fasting or intense physical activity [64, 67, 68]. 
An enhancement of cholesterol efflux to HDL may occur when the cholesterol 
content of the plasma membrane increases. In this case, mechanisms of cholesterol 
efflux, such as passive simple diffusion or transporter facilitated diffusion would lead to 
an increase in the rate of cholesterol efflux to apoA-I or HDL [12]. However, our study 
indicates that activation of lipolysis triggers a decrease in the cholesterol content of the 
plasma membrane. Therefore, the enhancement in the rate of cholesterol efflux to HDL 
cannot be attributed to the cholesterol content of the membrane. If this were the case we 
should expect a decrease in cholesterol efflux to HDL when lipolysis is activated. The 
biochemical mechanisms that affect the cholesterol content of the plasma membrane in 
adipocytes are not known. However, it seems that multiple stimuli can trigger changes in 
cholesterol content of the plasma membrane of adipocytes. Previous studies have shown 
that “obese adipocytes” contain a lower concentration of plasma membrane cholesterol 
than lean adipocytes [70]. Moreover, changes in the plasma membrane cholesterol were 
observed during the differentiation of adipocytes [69, 73]. 
The cholesterol transporters ABCAI and SR-BI play a significant role in the 
transfer of cholesterol between cells and extracellular acceptors [57, 91]. It has been 
shown that overexpression of the scavenger receptor BI leads to an increase in the rates 
of cholesterol efflux to HDL in a variety of cells [92-94]. A mechanism of enhancement 
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of efflux to HDL involving an increase in SR-BI expression could be involved in 
adipocytes. However, SR-BI is poorly expressed in adipose tissue [18] and our study 
showed no significant changes in the expression of SR-BI protein upon activation of 
lipolysis. For these reasons, a role of SR-BI expression on cholesterol efflux, or in the 
enhancement of cholesterol efflux associated to lipolysis, is unlikely. The role of ABCAI 
in mediating cholesterol efflux to HDL is not clear. It has been shown that  
overexpression of ABCAI in transfected macrophages does not increase the efflux of 
cellular cholesterol to HDL [46]. On the other hand, fibroblasts isolated from subjects 
with Tangier disease have a reduced efflux of cholesterol to HDL [79, 80] suggesting that 
ABCAI is somehow involved in the cellular transfer of cholesterol to HDL. Our study 
showed no significant changes in ABCAI levels and therefore the increase in efflux 
cannot be directly related to the expression of ABCAI. However, as discussed below, 
ABCAI may play an indirect role in the enhancement of cholesterol efflux that takes 
place when the lipolysis is activated. Given the unlikely direct roles of the levels of 
cholesterol and cholesterol transporters of plasma membrane in the enhancement of 
cholesterol efflux, a possible role of vesicular transport was investigated using BFA, 
which is known to alter vesicular lipid and protein transport by promoting fusion of Golgi 
and endoplasmic reticulum compartments [88, 89]. BFA was shown to inhibit cholesterol 
efflux to lipid free apoA-I while mimicking several of the cellular effects observed in 
cells isolated from patients affected by Tangier disease [42, 95, 96]. This study showed 
that cholesterol uptake by HDL is mostly unaffected by Brefeldin A under basal lipolytic 
conditions suggesting that BFA sensitive vesicular transport is not required for the basal 
output of cholesterol to HDL. On the other hand, BFA abolished the lipolysis-induced 
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enhancement of cholesterol efflux to HDL, suggesting that BFA-sensitive vesicular 
transport is necessary to allow the enhancement of cholesterol efflux that accompanies β-
adrenergic activation of the lipolysis. Since BFA has been shown to prevent the recycling 
of ABCAI from intracellular vesicles to the plasma membrane [42, 95], an indirect role of 
ABCAI in the enhancement of cholesterol efflux is possible. A mechanism of cholesterol 
efflux mediated by activation of vesicular transport could explain the apparent 
contradiction given by the fact that the release of cellular cholesterol increases when the 
cholesterol content of the plasma membrane is reduced. 
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CHAPTER III 
Cholesterol efflux and apoA-I recycling in adipose tissue 
Introduction 
Reverse cholesterol transport (RCT) is the process by which excess unesterified 
cholesterol (UC) is transported from peripheral tissues to the liver for excretion from the 
body [9, 10]. RCT is relevant because the peripheral cells acquire cholesterol through 
uptake of lipoproteins and de novo synthesis, but are unable to catabolize it. The free 
cholesterol (FC) efflux is one of the decisive early steps of the RCT and high-density 
lipoprotein (HDL) serves as the main transport vehicle for the cellular cholesterol 
released from the peripheral cells to liver [11]. Apolipoprotein A-I (apoA-I) is the major 
protein component of HDL that promotes the efficient transfer of excess peripheral cell 
cholesterol to make them an efficient acceptor and transporter. Deficiency and naturally 
occurring mutations in apoA-I fail to produce normal HDL levels and particles [13].  The 
plasma levels of HDL and apoA-I are inversely linked with the risk of cardiovascular 
diseases. Hence it is suggested that RCT is an important physiological process that 
protects against cardiovascular diseases [14].  
Several studies suggest that ABCAI is required for the initial and normal 
lipidation of apoA-I to from pre-beta HDL; an efficient acceptor molecule, intermediate 
to mature HDL (HDL-C). In the absence of ABCAI, the apoA-I is rapidly catabolized 
[97]. ABCAI is expressed widely through out the mice and human organs but the role and 
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contribution of each organ in HDL biogenesis is not known.  In the classical RCT model, 
the peripheral cells are the primary location for the pre-beta HDL biogenesis and these 
molecules are ultimately transferred as mature HDL to the liver [9, 10]. But a recent 
study in liver-specific ABCAI-knockout (KO) mice challenges the classical RCT model 
and proposed that the liver is the single most significant source of plasma HDL-C [54]. 
Another study with intestine specific ABCA-KO mice suggests that intestine also plays a 
significant role in the biogenesis of HDL through ABCAI receptor [55].  These studies 
suggest that the 2 organs that synthesize apoA-I are also primarily responsible for 
lipidating apoA-I through ABCAI. But the studies on the total peripheral cholesterol 
efflux contribution per day per kg of body weight in mice suggest an opposing view to 
the above 2 studies [56]. Even though muscle, adipose tissue, skin and other peripheral 
tissues express comparable or elevated amounts of cholesterol and ABCAI than liver and 
intestine, their significance in the contribution of lipid efflux by HDL biogenesis has not 
been studied. The tissue that contributes the greatest mass of cholesterol to the RCT 
process is also unknown. 
Adipose tissue contains more cholesterol than most other organs when expressed 
per protein or organ mass [56]. Thus, adipose tissue may contribute significantly to the 
biogenesis of HDL and RCT process. Because the capacity of cholesterol synthesis and 
catabolism of adipocytes is very low [64, 66], the cholesterol content of adipose tissue is 
dependent on the balance between efflux and influx of cholesterol.  
Our studies as well as others have shown that adipose tissue has the ability to 
efflux cholesterol to HDL and apoA-I [72, 73, 83]. The rate of cellular cholesterol 
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removal by apoA-I depends on the plasma membrane levels of cholesterol [13, 79] and 
ATP binding cassette transporter A1, ABCAI [80] in several cell lines. However, as is the 
case for most tissues, the mechanisms involved in cholesterol efflux in adipose tissue, 
and their relative contribution to the overall efflux process have not been fully 
established. This study was directed to gain insights into; a) new pathways of cholesterol 
efflux in adipocytes. b) the effect of lipolysis on the rate of cellular cholesterol efflux to 
lipid free apoA-I.  
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Experimental Procedures 
Materials: 3T3 L-1 cells were purchased from American Type Cell Culture 
(Manassas, VA). Polyclonal anti-ABCAI antibody was obtained from Novus-Biologicals 
(Littleton, CO). Monoclonal antibody for plasma membrane Na+K+-ATPase was 
purchased from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa 
City, IA). Horseradish peroxidase (HRP) tagged antibodies were purchased from Santa 
Cruz Biotechnology, Inc (Santa Cruz, CA). Fatty acid free bovine serum albumin, 
protease inhibitors (phenyl-methyl sulfonyl fluoride, leupeptin, aprotinin, antipain), 
isobutyl methyl xanthine (IBMX), dexamethasone, trypsin, biotin, sodium pyruvate, 
insulin, streptomycin and penicillin were purchased from Sigma Chemicals Co. (St. 
Louis, MO). Fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT). 
Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Cellgro Mediatech, 
Inc (Herndon, VA). [3H]-Cholesterol (60 Ci/mmoL) was from Perkin-Elmer (Waltham, 
Massachusetts). [32P] orthophosphate (carrier free) was purchased from MP 
Biochemicals. Chemiluminiscence kit for Western blots was obtained from Amersham 
Biosciences (Piscataway, NJ).  
 
Cell Culture and Lipoproteins: 3T3 L-1 pre-adipocytes were cultured at 37 0C in 
8% CO2 atmosphere in high glucose DMEM supplemented with 10% FBS and 0.01% 
streptomycin and penicillin antibiotics. One day after confluence, the differentiation into 
adipocytes was induced by addition of IBMX (111 µg/mL), dexamethasone (0.46 µg/ml), 
and insulin (1.5 µg/ml) in the medium that was also supplemented with biotin (4 µg/ml) 
and sodium pyruvate (100 µg/ml) [15]. After 48 h, the cells were incubated in DMEM/10 
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% FBS containing insulin, biotin, and sodium pyruvate for additional 48 h. Afterwards 
the cells were maintained in DMEM/10% FBS. All experiments were conducted 12 days 
after completion of the differentiation period.  
           Human lipid-free apoA-I was isolated, stored and prepared for cell culture studies 
as described previously [98]. Recombinant apoA-I was prepared by cloning full-length 
human apoA-I into a pET33b vector (Novagen), which incorporates an N-terminal tag 
encoding for a six-His tag and a five amino acid recognition sequence (RRASV) for the 
catalytic subunit of cAMP-dependent protein kinase (PKA) 
Cholesterol Efflux: Adipocytes cultured in six or twelve well dishes were 
radiolabeled by incubation for 24 h with [3H]-cholesterol (2 µCi/ml) in DMEM 
containing 2.5% FBS. The media was removed and the cells were incubated for 3 hours 
in serum-free DMEM containing 0.2% BSA (DMEM/BSA) and, before the beginning of 
the experiment, rinsed twice with DMEM/BSA. The experiment started by addition of 
fresh DMEM/BSA (basal lipolysis) or DMEM/BSA supplemented with 10 µg/ml of 
isoproterenol (high lipolysis). Cholesterol efflux to apoA-I was determined at 37 0C in the 
corresponding, basal or high lipolysis, media containing the acceptors at a concentration 
of 50 µg of apoA1/ml. Background cholesterol efflux was determined in the 
corresponding basal and high lipolysis media containing no acceptors.  Microliter 
aliquots of the medium were collected at specific time intervals to estimate the fraction of 
[3H]-cholesterol released into the medium by scintillation counting. At the end of the 
incubation, the cells were washed with phosphate buffered saline (PBS) twice and the 
lipids extracted with 2-propanol. The lipid extract was used to determine the fraction of 
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radiolabeled cholesterol remaining in the cells. Cholesterol efflux was expressed as the 
percentage of radiolabeled cholesterol released into the media as:  
100x [3H]-Cholesterol in media /([3H]-Cholesterol in media + [3H]-Cholesterol in cells).  
The effect of inhibitors on cholesterol efflux was studied by pre-incubating the 
pharmacological agents, BFA (10 µg/mL), Glyburide (500 µM), BLT-1(10 µM), and 
BLT-4 (150 µM) with [3H]-cholesterol labeled cell media for 2 h. After the 
preincubation, the cells were incubated for an additional 5 h at 37°C under the same 
concentrations of inhibitors in the presence or absence of 50 µg/ml lipid-free apoA-I to 
measure cholesterol efflux. Background cholesterol efflux was determined by adding 
corresponding drug solvents in the media containing no acceptors.  Microliter aliquots of 
the medium were collected at specific time intervals to estimate the fraction of [3H]-
cholesterol released into the medium by scintillation counting. Following the incubation, 
the cellular lipids and cell culture media were analyzed for radioactivity as described 
above. 
Isolation of Lipid Droplets. Lipid droplets were obtained as previously described 
[99].The post-nuclear supernatant containing 0.25 M sucrose was overlaid with 5.0 ml of 
50 mM Tris-HCl buffer containing, 1 mM EDTA and protease inhibitors, and centrifuged 
in a SW40 rotor for 3 h at 200,000 g and 4 °C. The lipid droplets were collected from the 
top layer.  
 
Lipolysis. The extent of lipolysis was estimated from the fatty acids released into 
the cell media. Non-esterified fatty acids were determined with the NEFA kit (Wako 
Chemicals USA, Inc).  
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Western Blots: Aliquots of the cell homogenate of 3T3L-1 (basal lipolysis), 
3T3L-1(high lipolysis), HEK 293, HepG2, J774.1 (un-stimulated), J774.1 (stimulated 
with 8-Br-cAMP (300 mM) for 16 hours) and PM and LD preparations of 3T3L-1 cells 
containing 20 µg of protein were mixed with reducing SDS-sample buffer and subjected 
to SDS-PAGE in 8% acrylamide gels. The proteins were transferred to a nitrocellulose 
membrane and probed with a rabbit anti mouse/human ABCAI (1:750 dilution), and anti-
SR-BI (1:1000). Parallel Western blots were run to determine the abundance of Na+/K+ 
ATPase using a monoclonal anti- Na+/K+ ATPase antibody (1:10 dilution). All secondary 
antibodies were used at a 2500 fold dilution. The bands were visualized by 
chemiluminescence and quantified by densitometry. 
ApoA-I cellular Uptake and Re-secretion. Full-length recombinant human apoA-
I was cloned into a pET33b vector (Novagen), which incorporates an N-terminal tag 
encoding for a six-His tag and a five amino acid recognition sequence (RRASV) for the 
catalytic subunit of cAMP-dependent protein kinase (PKA). The protein was expressed in 
E. coli and purified by Ni-affinity chromatography. The activity and specificity of PKA 
against recombinant apoA-I was tested by in vitro phosphorylation with bovine PKA and 
γ-[32P]-ATP. Human apoA-I isolated from serum was not phosphorylated by PKA 
whereas the recombinant protein was highly phosphorylated by PKA.  
In vivo Phosphorylation of apoA-I and PKA specificity: 3T3-L1 fibroblasts 
derived adipocytes cultured in six well dishes were double radiolabeled by incubation for 
4 h with 80 µCi/well of [32P] orthophosphate (carrier free) and 2 µCi/ml [1,23H]-
cholesterol for 24 h at 370C in phosphate-free DMEM containing 0.12% BSA. At the end 
of the labeling period, 10 ug/mL isoproterenol (high lypolysis), DMSO (basal lipolysis) 
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and PKA inhibitor H-89 (40 µM) were added to the appropriate wells. Recombinant 
apoA-I (50 µg) was also added immediately and cell media collected at 60 and 120 
minutes. The collected cell media was loaded into a Ni-affinity columns, the columns 
were extensively washed with 20 mM imidazole and eluted the recombinant apoA-I with 
1M imidazole. The eluted proteins were separated by SDS-PAGE on 4-20% gels and 
subjected to autoradiography to visualize the phosphorylation. 
Kinetics of apoA-I phosphorylation: The kinetic of apoA-I phosphorylation was 
monitored by incubating the [32P] orthophosphate (carrier free) pre-labeled cells with 10, 
20, 40 80 and 100 micrograms of recombinant apoA-I per milliliter of cell media. After 
the incubation of apoA-I for 40 min, the proteins in the cell media were separated by 
SDS-PAGE on 4-20% gels. The gels were subjected to autoradiography to visualize the 
phosphorylation. 
Competition Assay: The specificity of apoA-I phosphorylation was monitored by 
incubating the [32P] orthophosphate (carrier free) pre-labeled cells with a 40 microgram 
of recombinant apoA-I per milliliter of cell media and 10, 20, 40, 80 and 160 microgram 
of  human apoA-I  per milliliter of cell media. After incubation for 40 min, the proteins in 
the cell media were separated by SDS-PAGE on 4-20% gels. The gels were subjected to 
autoradiography to visualize the phosphorylation.  
  Inhibitor study on uptake and re-secretion: The effect of inhibitors on 
retroendocytosis was studied by pre-incubating the pharmacological agents, BFA (10 
µg/mL), Glyburide (500 Na+/K+ M), and BLT-1(10 µM), with [3H]- labeled and [32P] 
orthophosphate (carrier free)  cell media for 2 h. After the preincubation, the cells were 
incubated for an additional 40 min at 37°C with the same concentrations of inhibitors in 
 43 
the presence or absence of 50 microgram of apoA-I per milliliter of cell media. After 
incubation for 40 min, the proteins in the cell media were separated by SDS-PAGE on 4-
20% gels. The gels were subjected to autoradiography to visualize the phosphorylation.  
Lipid Extraction: To determine the phospholipid and cholesterol acquired by 
apoA1 during the efflux process, the lipids in the eluted protein were extracted with 2:1 
chloroform/ methanol mixture. The organic phase was collected and dried. The lipids 
were separated by thin layer chromatography (TLC) on Silica Gel K6 plates using 
chloroform/methanol/water (50:25:4) as the developing solvent. The phospholipids spots 
were visualized by autoradiography and the spots corresponding to cholesterol were 
scraped and their radioactivity determined by liquid scintillation counting. 
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Results 
Cellular cholesterol efflux to apoA-I 
The rate of cholesterol efflux to human plasma apoA-I was studied in adipocytes 
that were pre-labeled with [3H]-cholesterol for 24 h. Under these conditions 96% of the 
radiolabeled cholesterol in adipose tissue is found as such, and the remaining 4% is found 
as cholesterol esters. This distribution of radiolabeled cholesterol is nearly identical to the 
relative mass contents of cholesterol and cholesterol ester previously reported for 
adipocytes [65, 66, 73] suggesting that in 24 h the incorporated radiolabeled cholesterol 
reaches a physiological distribution. 
A representative time course of cholesterol efflux to apoA-I (50 µg/mL) is shown 
in figure 7. The amounts of [3H] cholesterol in the incubation media and the amounts 
remaining associated with the cells were measured, and efflux was expressed as the 
percentage of cellular [3H] cholesterol released into the medium during the 5 h 
incubation. At the concentration of lipoprotein tested (50 µg apoA-I/ml), and after 5 h of 
incubation, the total cellular cholesterol efflux is approximately 2.8% and lipid free 
apoA-I induced cholesterol efflux is approximately 1.8% of the total cellular cholesterol.  
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Fig. 7.  Cellular Cholesterol Efflux from Adipocytes to Lipid Free apoA-I.  Time course of cholesterol 
efflux: Adipocytes grown in six-well plates were labeled with [3H]-cholesterol and incubated for 5 h at 
370C in DMEM containing lipid-free apoA-I (50 µg/ml). Samples from three wells were taken at different 
time points. Following the incubation, the cellular lipids and cell culture media were analyzed for 
radioactivity. The mean fraction % of radiolabeled cholesterol detected in the media is shown in the graphs. 
The apoA-I induced cholesterol efflux values were obtained by subtracting the total cholestrol efflux values 
(apoA-I (50 ug/mL) from background efflux values (without apoA-I incubation). The data plotted is 
average value of two independent experiments with three internal replicates ± SD) 
 
Effect of lipolysis on the rate of cholesterol efflux from adipocytes to apoA-I. 
  To examine the effect of lipolysis on cholesterol efflux to lipid free apoA-I, [3H]-
cholesterol prelabeled cells were incubated in DMEM/BSA in the absence or in the 
presence of the non-specific β-adrenergic agonist, isoproterenol. In the presence of 
isoproterenol, the rate of lipolysis, as estimated from the fatty acids released into the 
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incubation media, increases ~7-8 fold, from ~3.2 to ~27 nmol FA/mg of cellular 
protein/h.  
Figure 8 shows the effect of lipolysis on the rate of cholesterol efflux to the lipid 
free human and recombinant apoA-I acceptor. The figure shows the average values of 
rate of cellular cholesterol efflux per minute obtained when adipocytes were incubated in 
DMEM/BSA containing apoA-I (50 µg/ml). The amounts of [3H] cholesterol in the 
incubation media and the amounts remaining associated with the cells were measured, 
and efflux was expressed as the percentage of cellular [3H] cholesterol released into the 
medium/min during the 5 h incubation. The data shows that activation of lipolysis does 
not induce a significant increase in the rate of cholesterol efflux to lipid free human 
apoA-I; 0.0043%/min, ±0.0006 and 0.0050%/min, ±0.0007 (P>0.05) and recombinant 
apoA-I; 0.0041%/min, ±0.0008 and 0.0050%/min, ±0.0013 (P>0.05). 
The data in figure 8 also demonstrate that the human lipid free apoA-I and 
recombinant apoA-I have the same cholesterol efflux kinetic characteristics. Since the 
efflux properties are the same for human lipid free apoA-I, a recombinant apoA-I 
containing an N- terminal histidine tag and protein kinase A (PKA) site was used for 
further experiments. 
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Fig 8. Effect of Lipolysis on the Rate of Cholesterol Efflux to apoA-I. Adipocytes grown in six-well 
plates were labeled with [3H]-cholesterol and incubated for 5 h at 370C in DMEM containing lipid-free 
human apoA-I (h-apoA-I) and recombinant apoA-I (r-apoA-I) (50 µg/ml). “High lipolysis” and “Basal 
Lipolysis” refer to cells incubated in the corresponding media with or without isoproterenol (10 µg/ml), 
respectively. Samples of the media were collected at 5 h and analyzed for radioactivity. The mean fraction 
% of radiolabeled cholesterol detected in the media is shown in the graphs. The data plotted (average value 
of four independent experiments ± SE) were corrected for radiolabeled cholesterol released in the absence 
of acceptor.  
 
Effects of inhibitors on ABCAI and SR-BI-mediated cholesterol efflux to apoA-I 
ABCAI and SR-BI are abundantly expressed in liver, macrophages, intestine, 
brain, kidney, steroidogenic and endothelial cells. ABCAI is up-regulated with cyclic 
AMP analog in macrophages and several other cell types. The cyclic AMP induced up-
regulation was exploited to study the ABCAI function in these cell types. 
 Figure 9 A shows that adipose cells abundantly express ABCAI in comparison 
with cells that are known to have high expression, like HepG2 (human liver cells) and 
cAMP stimulated J774.1(macrophage cells). HEK293 (kidney cells) is known to express 
low levels of ABCAI.  
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The cyclic AMP analog and apoA-I does not up-regulate the ABCAI expression in 
adipose cells (Fig. 9 B). The SR-BI is adequately expressed in adipose cells and does not 
up-regulate the expression with cyclic AMP treatment (Fig. 9 C). 
 
 
 
 
 
 
 
Fig. 9 ABCAI Protein Content In Adipose Tissue And Other Cell Lines A) Western blot showing 
ABCAI protein levels in homogenates of different cell lines. Western blot was performed after separating 
20 µg of protein/sample by SDS-PAGE, as described in experimental procedures. B) Western blotting of 
Na+/K+ ATPase and ABCAI of plasma membrane of 3T3L-1 adipocytes was performed after separating 15 
µg of protein/sample by SDS-PAGE, as described in experimental procedures. The samples were obtained 
after incubation of the cells for 5 h in the absence or in the presence of isoproterenol (without acceptors); 
lane 1&2 respectively and cholesterol acceptor apoA-I (50 µg of protein/ml); lane 3 and cholesterol 
acceptor apoA-I and isoproterenol; lane 4. C) Western blot of SR-BI receptor from plasma membranes of 
adipocytes incubated for 5 h in DMEM; lane 1, or in DMEM containing isoproterenol, lane 2 .  
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To gain quantitative data on the contribution of cholesterol efflux pathways in 
relation to lipid free apoA-I in adipocytes, we used 4 inhibitors which are previously 
shown to inhibit receptor mediated ((Glyburide, Block Lipid Transfer-1&4 (BLT-1 & 
BLT-4)) and non-receptor mediated pathways (BFA) in other cell lines.  BFA, the most 
extensive studied inhibitor, blocks the vesicular lipid and protein transport by promoting 
fusion of Golgi and endoplasmic reticulum compartments in the cells [89]. It is reported 
that Glyburide and BLT-4 blocks the ABCAI and apoA-I dependent pathway and BLT-1 
blocks HDL and SR-BI mediated pathway in cultured cell lines. The above mentioned 
inhibitors, glyburide, BLT-1 and BLT-4 have not been studied in adipose tissue in 
relation to cholesterol efflux. 
  Cholesterol efflux was measured from cells labeled with [3H]-cholesterol for 24 h, 
followed by a 2 h preincubation with inhibitors. This was followed by a 5 h incubation 
with inhibitors in the presence of 50 µg of protein per milliliter of lipid-free apoA-I. The 
amounts of [3H] cholesterol in the incubation media and the amounts remaining 
associated with the cells were measured, and efflux was expressed as the percentage of 
cellular [3H] cholesterol released into the medium during the 5 h incubation.  
Figure 10A shows that the rates of cholesterol efflux to lipid free apoA-I in the 
presence of inhibitors. The non-receptor mediated BFA (10 g/mL) had a 63% inhibition 
in cholesterol efflux to apoA-I (Fig. 10 B). The ABCAI and apoA-I mediated inhibitors,  
glyburide (500 µM ) and BLT-4 (150 µM) had 99% and 50% inhibition respectively and 
the SR-BI and HDL mediated inhibitor, BLT-1(10 µM) had 40 % inhibition in 
cholesterol efflux to apoA-I (Fig. 10 B). The inhibition studies suggested that i) lipid free 
apoA-I mediated cholesterol efflux may involve both receptor mediated and non-receptor 
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mediated vesicular transport. ii) ABCAI may play an important role in the lipid free 
apoA-I mediated cholesterol efflux, since glyburide and BLT-4 significantly inhibited the 
cholesterol efflux ii) in addition of vesicular transport and ABCAI mediated pathways 
several other pathways may exist. 
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Fig. 10 Effect of Inhibitors on Cellular Cholesterol Efflux from Adipocytes to Lipid Free apoA-I.  
Adipocytes grown in six-well plates were labeled with [3H]-cholesterol and then preincubated for 2 h at 
37°C in assay medium containing  DMSO and indicated concentrations of BFA, Glyburide, BLT-1, and 
BLT-4 . After preincubation, the cells were incubated for an additional 5 h at 37°C with the same 
concentrations of inhibitors in the presence or absence of 50 µg/ml lipid-free apoA-I to measure cholesterol 
efflux. Following the incubation, the cellular lipids and cell culture media were analyzed for radioactivity. 
A) rate of cholesterol efflux/min to lipid free apoA-I in the presence of inhibitors. B) percentage inhibition 
of cholesterol efflux to apoA-I. The data plotted is average value of three independent experiments ± SD) 
A 
B 
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Uptake and re-secretion of apoA-I by 3T3L-1 adipocytes 
The stored lipids in adipose tissue are in a specialized organelle called lipid 
droplets. Adipose tissue constitutes one of the largest reservoirs of cholesterol in 
vertebrates [61]. Cellular cholesterol of adipocytes resides more in lipid droplets than PM 
and most of the lipid-droplet cholesterol is found in the non-esterified form.  The high 
amount of intracellular cholesterol depot, receptor sensitive inhibitor studies and the 
presence of ABCAI in the lipid droplet (Fig. 11) prompted to us to gain further insights 
into the possible pathways involved in apoA-I mediated cholesterol efflux. Hence we 
investigated the ability of adipocytes to internalize and re-secrete apoA-I into the cell 
medium (retroendocytosis). 
This question was investigated using a novel approach in which a full-length 
recombinant human apoA-I with an N terminal five amino acid recognition sequence 
(RRASV) for the catalytic subunit of cAMP-dependent protein kinase (PKA) was 
constructed. The protein was expressed in E. coli and purified by Ni-affinity 
chromatography. The activity and specificity of PKA against recombinant apoA-I was 
tested by in vitro phosphorylation with bovine PKA and γ-[32P]-ATP. Human apoA-I 
isolated from serum was not phosphorylated by PKA whereas the recombinant protein 
was highly phosphorylated by PKA (Fig. 12).  
  This apoA-I variant allowed studying uptake and re-secretion of apoA-I through 
the appearance of phosphorylated apolipoprotein in the cell culture medium. Because 
protein phosphorylation can only occur intracellularly, the presence of phosphorylated 
apoA-I in the cell medium clearly indicates that the protein was internalized and 
subsequently secreted by the cell. 3T3L-1 fibroblasts derived adipocytes cultured in six 
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well dishes were double radiolabeled by incubation for 4 h with 80 µCi/well of [32P] 
orthophosphate (carrier free) and 2 µCi/ml [3H]-cholesterol for 24 h at 370C in phosphate-
free DMEM containing 0.12% BSA. At the end of the incubation period cell media was 
collected at different time points and loaded into a Ni-affinity column to purify the 
recombinant apoA-I. The eluted proteins were separated by SDS-PAGE on 4-20% and 
subjected to autoradiography to determine the phosphorylation.  
The data in figure 13 A demonstrates the presence of phosphorylated apoA-I in 
the medium of control cells; (low lipolysis), or in the medium of cells incubated with 
isoproterenol; (high lipolysis). Also the phosphorylation of apoA-I observed in low and 
high lipolysis is sensitive to the PKA inhibitor, H-89 (Fig.13 A). The intensity of 
phosphorylation of apoA-I in the medium from control cells was lower than that observed 
in the medium of cells with high rate of lipolysis (Fig. 13 B). Most of this difference is 
probably due to the fact that PKA is activated by isoproterenol, which is a β-adrenergic 
agonist. However, the novel approach used evidently showed retroendocytosis of apoA-I 
in adipose cells.  
To show that the recycling apoA-I is lipid loaded, the phospholipid and 
cholesterol acquired during the recycling process is extracted with chloroform/ methanol 
mixture. The figure 14 shows a representative autoradiogram of the phosphatidylcholoine 
spots separated in a TLC plate. The separated cholesterol spots were scraped and 
scintillation counted to determine the specific cholesterol efflux to apoA-I, which is 
similar to the results discussed earlier (data not shown).  
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Fig. 11. ABCAI in Lipid Droplet of 3T3L-1: Western blotting of  lipid droplet of 3T3L-1 adipocytes was 
performed after separating 15 µg of protein/sample by SDS-PAGE, as described in experimental 
procedures. The samples were obtained after incubation of the cells for 5 hours in the absence or presence 
of the cholesterol acceptor apoA-I . Lane 1&3: shows control (low lipolysis) cells incubated with and 
without apoA-I respectively. Lane 2&4: shows cells incubated with isoproterenol ( high lipolysis) with and 
without apoA-I respectively. 
 
Fig. 12. In vitro Phosphorylation of Recombinant Lipid Free apoA-I: The specificity of PKA against 
recombinant apoA-I was tested with commercially purchased bovine PKA and γ-[32P]-ATP as described in 
experimental procedures. Lane 1: recombinant apoA-I with PKA site. Lane2: B human apoA-I isolated 
from serum.  
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Fig. 13. Uptake and Re-secretion of apoA-I in Adipose Cells: 3T3L-1 adipocytes were radiolabeled by 
incubation with 2 µCi/ml [3H]-cholesterol  for 24 h and for 4 h at 370C with 80 µCi/ml of [32P]-phosphate 
in phosphate-free DMEM containing 0.12% BSA. Cellular uptake and subsequent re-secretion of apoA-I 
was monitored by incubating the pre-labeled cells with recombinant apoA-I (50µg/ml) containing a 
phosphorylation site for PKA. After incubation for 60 and 120min, apoA-I was purified from the cell 
culture media by Ni-affinity chromatography. Proteins were separated by SDS-PAGE on 4-20% gels. 
Panel A shows the apoA-I region of the Coomassie Blue-stained gel (upper) and the corresponding 
autoradiogram (lower). The cells were incubated in the same experimental condition with H-89 PKA 
inhibitor as indicted in the figure. Panel B shows the corresponding normalized phosphorylation of panel A 
 Left panel purified apoA-I from the medium of cells with low lipolysis); Right panel: purified apoA-I 
from the medium of cells incubated with apoA-I with high lipolysis.  
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Fig. 14. Lipidatated apoA-I of Retroendocytosis. 3T3L-1 adipocytes were radiolabeled by incubation 
with 2 µCi/ml [3H]-cholesterol  for 24 h and for 4 h at 370C with 80 µCi/ml of [32P]-phosphate in 
phosphate-free DMEM containing 0.12% BSA. Cellular uptake and subsequent re-secretion of apoA1 was 
monitored by incubating the pre-labeled cells with recombinant apoA-I (50µg/ml) containing a 
phosphorylation site for PKA. apoA-I from the corresponding time points were purified from the cell 
culture media by Ni-affinity chromatography. Aliquot of purified protein was used to extract lipids by 
chloroform/ methanol mixture and separated by TLC. The autoradiograph of the TLC spots; 
Phosphatidylcholine and Phosphatidylethanolamine is shown. 
 
 
Figure 15 shows that the apoA-I phosphorylation in adipocytes increases with 
increasing concentration of apoA-I up to 100 µg of protein per milliliter. The apoA-I 
phosphorylation is also sensitive to the human apoA-I competition (Fig. 16). This 
suggests that recombinant apoA-I recycling pathway is specific and occurs through the 
same pathway as of human apoA-I. 
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Fig. 15. Uptake and Re-secretion Increases with Increasing apoA-I Amount in Media.  apoA-I 
phosphorylation increase with 3T3L-1 adipocytes were radiolabeled by incubation with 80 µCi/ml of [32P]-
phosphate in phosphate-free DMEM containing 0.12% BSA for 4 h. Cellular uptake and subsequent re-
secretion of apoA-I was monitored by incubating the pre-labeled cells with recombinant apoA-I with 
various amounts. After incubation for 1 h, the proteins in the cell media were separated by SDS-PAGE on 
4-20% gels. Panel A shows the apoA-I region of the Coomassie Blue-stained gel. Panel B shows the 
corresponding autoradiogram of the Coomassie Blue-stained gel. Panel C shows the corresponding 
normalized phosphorylation of panel A & B 
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  Fig. 16.  The Retroendocytosis of apoA-I is Specific: 3T3L-1 adipocytes were radiolabeled by 
incubation with 80 µCi/ml of [32P]-phosphate in phosphate-free DMEM containing 0.12% BSA for 4 h. 
The specificity of uptake and re-secretion was monitored by incubating the pre-labeled cells with a constant 
amount of recombinant apoA-I and a varying amount of human apoA-I isolated from serum. After 
incubation for 1 h, the proteins in the cell media was collected and  were separated by SDS-PAGE on 4-
20% gels. Panel A & B shows the apoA-I regions of the Coomassie Blue-stained gel (upper) and the 
corresponding autoradiogram (lower). Panel C shows the corresponding normalized phosphorylation of 
apoA-I. 
 
To further investigate the mechanism of retroendocytosis of apoA1 in adipocytes, 
the phosphorylation was measured from 3T3L-1 cells double labeled with [3H] 
cholesterol and [32P] orthophosphate (carrier free)  for 24 and 4 h respectively, followed 
C 
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by a 2 h preincubation with inhibitors, which was followed by a 40 min incubation with 
inhibitors in the presence and absence of 50 µg of protein per milliliter of lipid-free apoA-
I. At the end of the incubation period cell media was collected at different time points and 
loaded into a Ni-affinity column to purify the recombinant apoA-I. The eluted proteins 
were separated by SDS-PAGE on 4-20% gel and subjected to autoradiography to 
determine the phosphorylation.  
Figure 17, Panel A&B shows the phosphoylation of apoA-I in the presence and 
absence of inhibitors. Figure 17 C shows the rate of phosphorylation of apoA-I 
normalized for the protein amount and Panel D shows the phosphorylation of apoA-I 
normalized for protein amount and rate of  lipolysis (rate of lipolysis relates to the level 
of PKA activity in cells) in the presence and absence inhibitors. The results suggest that 
the rate of apoA-I uptake and re-secretion is independent of receptor and non-receptor 
sensitive drugs used in this study.  
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Fig. 17. Retroendocytosis of apoA-I is not Blocked by Inhibitors in Adipose Cells :3T3L-1 adipocy 
Fig. 17. Retroendocytosis of apoA-I is not blocked by inhibitors in adipose cells: 3T3L-I adipocytes 
were radiolabeled by incubation with 2 µCi/ml [3H]-cholesterol  for 24 h and for 4 h at 370C with 80 
µCi/ml of [32P]-phosphate in phosphate-free DMEM containing 0.12% BSA. Cellular uptake and 
subsequent re-secretion of apoA-I was monitored by incubating the pre-labeled cells with recombinant 
apoA-I (50 µg/ml) containing a phosphorylation site for PKA in the presence or absence of inhibitors; 
BFA, Glyburide, and BLT-1 as described in experimental procedures. After incubation for 10, 20 and 40 
min, apoA-I was purified from the cell culture media by Ni-affinity chromatography. Proteins were 
separated by SDS-PAGE on 4-20% gels. Panel A &B shows the apoA-I region of the Coomassie Blue-
stained gel and (upper) and the corresponding autoradiogram (lower). Panel C shows the corresponding 
phopshorylation of apoA-I normalized with protein amount. Panel D shows the corresponding 
phopshorylation of apoA-I normalized with protein amount and rate of lipolysis. 
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Discussion 
Our previous study established a metabolic link between lipolysis and rHDL 
cholesterol efflux in adipocyte. The investigation of the effect of the lipolytic state and 
rate of cellular cholesterol efflux is of interest in adipocytes because of its large content 
of stored unesterified cholesterol and role in energy homeostasis. Due to the large amount 
of free cholesterol stored in adipose tissue compared to most other organs, including liver 
and muscle, it could play a major role in the homeostasis of cholesterol metabolism. In 
continuation with our previous study, the current study investigated the effect of lipolysis 
on apoA-I cholesterol efflux, the major apolipoprotein of HDL in circulation. Data from 
this study shows that the activation of  lipolysis does not increase adipocyte cholesterol 
efflux to apoA-I. This observation does not undermine the link existing between lipolysis 
and cholesterol efflux. But the data suggests that lipid free apoA-I is not an efficient 
acceptor like pre β –HDL and may interact with different lipid domains in PM or 
intracellular location for the cholesterol absorption. This confines the ability of apoA-I to 
access the modulated cholesterol domains of membranes in the cells during the activation 
of lipolysis. It has been shown that apoA-I interacts with non-lipid raft domains in the 
PM and rHDL has the ability to interact with both non-lipid raft and lipid raft domains in 
macrophages and other cell lines [100-104]. 
It is very important to understand the apoA-I cholesterol efflux pathways, because 
of its prime role in the biogenesis of HDL. ABCAI and SR-BI are the two known cell 
receptor proteins that mediate apoA-I and HDL cholesterol efflux. The lipoproteins and 
receptors play an important role in cholesterol metabolism in mammalian system and 
abnormality in these components are correlated with far-reaching pathologies [31, 105]. 
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This study shows that apoA-I induced cholesterol efflux in adipocytes at 5 h period is 1.8 
% of the total cellular cholesterol (fig. 7) and the efflux is dose dependent (data not 
shown). Several pharmacological drugs have been demonstrated to inhibit ABCAI and 
SR-BI mediated free cholesterol efflux in several cell lines. Glyburide inhibits ABCAI 
mediated lipid efflux in macrophage cells, muscle cells, fibroblasts HEK293 cells, by 
reducing apoA-I binding to cell surface [15, 38, 106]. BLT-1 inhibits SR-BI receptor 
mediated efflux to lipoproteins while BLT-4 blocks both ABCAI and SR-BI in HEK293 
cells [32]. BFA blocks vesicular transport in cells. The efficacy to specifically inhibit 
cholesterol efflux pathways and mechanism of inhibition of these pharmacological agents 
will provide new insights in the understanding of cholesterol efflux process in adipose 
cells. In this study, the tested cholesterol efflux inhibitors, BFA, glyburide, BLT-1 and 
BLT-4 inhibited apoA-I induced cholesterol efflux significantly. The inhibition of 
ABCAI and SR-BI receptors and vesicular transport by the drugs suggested that apoA-I 
induce cholesterol efflux through multiple pathways in adipose cells. These cholesterol 
efflux pathways could be activated through vesicular transport (with and without the 
involvement of receptors), ABCAI, SR-BI, ABCGI and other unidentified pathways and 
receptors.  
The stored lipids in adipose tissue are in a specialized organelle called LD. The 
adipose tissue constitutes one of the largest reservoirs of free cholesterol in vertebrates 
[61]. Cellular cholesterol of adipocytes resides more in LD than PM and most of the 
lipid-droplet cholesterol is found in the non-esterified form (Fig. 2 A). Studies in 
macrophages and endothelial cells suggest that HDL and apoA-I bind to cell surface 
receptors, internalize, transport to non-lysososmal compartments and remove cholesterol 
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from intracellular locations. Finally, the lipoproteins are secreted from the cells to tissue 
culture media without degradation [34, 39, 42]. But a different study did not find 
evidence for lipoprotein internalization in macrophages cells [40]. At present the HDL 
and apoA-I retroendocytosis is under debate.  
The higher amount of intracellular cholesterol present in LD than PM, the 
decrease of cholesterol content in the PM during the activation of lipolysis [83], receptor 
sensitive inhibitor studies and the presence of ABCAI in the lipid droplet led us to the 
hypothesize that adipocytes have the ability to internalize and re-secrete apoA-I into the 
cell medium and play a potential role in the cholesterol homeostasis. The 
retroendocytosis studies are still under dispute mainly because of the ambiguous 
techniques employed in studying this process. 125I labeled apoA-I, apoA-I-green 
fluorescent protein (GFP) fusion protein and electron microscopy techniques are 
commonly used to study retroendocytosis. But the biochemical evidence for this process 
is mainly obtained from data of 25I experiments. This technique has serious limitations in 
identifying the membrane bound, internalized and re-secreted lipoproteins because the 
externally residing lipoproteins and re-secreted lipoprotein cannot be distinguished. 
 
To investigate the possibility of up-take and re-secretion of apoA-I in adipose 
cells, we used a novel approach in which a full-length recombinant human apoA-I with 
an N terminal five amino acid recognition sequence (RRASV) for the catalytic subunit of 
cAMP-dependent protein kinase (PKA) was constructed. Because the protein 
phosphorylation can only occur intracellularly, the presence of phosphorylated apoA-I in 
the cell medium clearly indicates that the protein was internalized and subsequently 
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secreted by the cell. The constructed recombinant protein was further tested for their 
phosphorylation ability and PKA specificity in vitro and in vivo. Our studies 
unambiguously showed that adipose cells uptake and re-secrete lipidated apoA-I in time 
specific manner. The uptake and re-secretion of recombinant apoA-I is challenged by 
native human apoA-I. This suggests that both recombinant and native apoA-I share a 
common pathway for internalization and secretion. We have used BFA (vesicular 
sensitive), Glyburide (ABCAI inhibition), and BLT-1 (SR-BI inhibition) to further 
understand the pathway of recycling of apoA-I in adipose tissue. At the concentration 
used, all three drugs had no effect on the uptake and recycling of apoA-I in adipose 
tissue. The autoradiograph of the gluburide inhibitor study shows decreased 
phosphorylation of re-secreted apoA-I. This decreased phosphorylation observed is due 
to the inhibition of cellular lipolysis by glyburide. Once the phophorylation was 
normalized for protein amount and rate of lipolysis, the glyburide treatment showed no 
significant inhibition effect compared to the control experiments.  This also shows that 
glyburide interferes with cellular process other than its known actions. In conclusion, we 
clearly show that adipose tissue uptakes and re-secretes lipidated apoA-I molecules. The 
observed retroendocytosis may not occur through the known receptors or components of 
cholesterol efflux. Several cell lines express low levels of ABCAI, SR-BI and ABCGI 
but have normal cholesterol efflux and function through poorly identified or unidentified 
pathways [107]. The contribution of cholesterol efflux by retroendocytosis and the 
physiological relevance of this process is unknown. 
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In brief our studies show that activation of lipolysis does not induce a significant 
increase in the rate of cholesterol efflux to lipid free apoA-I. The known vesicular and 
non-vesicular cholesterol efflux inhibitors inhibit global cholesterol efflux significantly. 
We have evidently presented that lipid free apoA-I undergo retroendocytosis in adipose 
tissue and the cholesterol efflux drugs had no effect on the uptake and recycling of apoA-
I. 
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CHAPTER IV 
Cholesterol efflux and apoA-I recycling in macrophages 
Introduction 
Reverse Cholesterol Transport (RCT) is relevant because peripheral cells acquire 
cholesterol through uptake of lipoproteins and de novo synthesis, but are unable to 
catabolize it. The free cholesterol (FC) efflux is one of the decisive early steps of the 
RCT and high-density lipoprotein (HDL) serves as the main transport vehicle for the 
cellular cholesterol released from the peripheral cells to liver [11]. Apolipoprotein A-I 
(apoA-I) is the major protein component of HDL that promotes the efficient transfer of 
excess peripheral cell cholesterol to make them an efficient acceptor and transporter. 
Deficiency and naturally occurring mutations in apoA-I fail to produce normal HDL 
levels and particles [13].  The plasma levels of HDL and apoA-I are inversely linked with 
the risk of cardiovascular diseases. Hence it is suggested that RCT is an important 
physiological process that protects against cardiovascular diseases [14].  
Monocyte derived macrophage cells accumulate cholesterol ester (CE) rich 
lipoproteins like LDL and apolipoprotein B (apoB) containing particles from plasma and 
vascular compartments via specific receptors [24, 108]. The CE and lipid rich 
macrophages morphologically appear as foam cells. These foam cells are the hallmark of 
early and intermediate atherosclerotic lesions [109].  HDL and apoA-1 stimulate 
cholesterol efflux from macrophage foam cells and reduce cholesterol accumulation and 
atherogenesis in animals [110-112]. The overall contribution of macrophages in the 
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cholesterol homeostasis and RCT process is unknown but in relation to atherosclerosis, 
macrophage-specific RCT is extremely crucial in preventing the disease.  
Macrophage cholesterol efflux has been extensively studied. Several of these 
studies suggested that the reteroendocytosis of lipoproteins occur in macrophages for 
cholesterol efflux [27, 36-39]. But the retroendocytosis of lipoproteins in macrophages or 
other cell lines are under intense debate because of the ambiguous techniques employed 
to elucidate this process. In this study we aim to determine the uptake and re-secretion of 
apoA-I in macrophages with an unambiguous technique. 
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Experimental Procedures 
 
Materials: J774.1 macrophage cells were purchased from American Type Cell 
Culture (Manassas, VA). Polyclonal anti-ABCAI antibody was obtained from Novus-
Biologicals (Littleton, CO). Horseradish peroxidase (HRP) tagged antibodies were 
purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Fatty acid free bovine 
serum albumin, protease inhibitors (phenyl-methyl sulfonyl fluoride, leupeptin, aprotinin, 
antipain), 8-Br-cAMP, streptomycin and penicillin were purchased from Sigma 
Chemicals Co. (St. Louis, MO). Fetal bovine serum (FBS) was obtained from Hyclone 
(Logan, UT). Dulbecco’s modified Eagle’s medium (DMEM) was purchased from 
Cellgro Mediatech, Inc (Herndon, VA). [3H]-Cholesterol (60 Ci/mmoL) was from 
Perkin-Elmer. [32P] orthophosphate (carrier free) was purchased from MP Biochemicals. 
Chemiluminiscence kit for Western blots was obtained from Amersham Biosciences 
(Piscataway, NJ).  
Cell Culture and Lipoproteins: J774.1 cells were cultured at 37°C in 8% CO2 
atmosphere in high glucose DMEM supplemented with 10% FBS and 0.01% 
streptomycin and penicillin antibiotics. All experiments were conducted when cells were 
at 85%-90% confluence.  
           Recombinant apoA-I was prepared by cloning full-length human apoA-I into a 
pET33b vector (Novagen), which incorporates an N-terminal tag encoding for a six-His 
tag and a five amino acid recognition sequence (RRASV) for the catalytic subunit of 
cAMP-dependent protein kinase (PKA) 
Cholesterol Efflux: J774.1 macrophage cells in 12 well dishes were stimulated 
with 8-Br-cAMP and radiolabeled with 2 µCi/ml [3H]-cholesterol for 24 h. The media 
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was removed and the cells were incubated for 3 hours in serum-free DMEM containing 
0.2% BSA (DMEM/BSA) and, before the beginning of the experiment, rinsed twice with 
DMEM/BSA. The experiment was started by addition of fresh DMEM/BSA with 8-Br-
cAMP. Cholesterol efflux to apoA-I (50 µg/mL) was determined at 37 0C in the media of 
cells that were stimulated with 8-Br-cAMP for 24 h and control cells with 8-Br-cAMP 
added just before the experiments. Background cholesterol efflux was determined in the 
media containing no acceptors.  Microliter aliquots of the medium were collected at 
specific time intervals to estimate the fraction of [3H]-cholesterol released into the 
medium by scintillation counting. At the end of the incubation, the cells were washed 
with phosphate buffered saline (PBS) twice and the lipids extracted with 2-propanol . The 
lipid extract was used to determine the fraction of radiolabeled cholesterol remaining in 
the cells. Cholesterol efflux was expressed as the percentage of radiolabeled cholesterol 
released into the media as:  
100x [3H]-Cholesterol in media /([3H]-Cholesterol in media + [3H]-Cholesterol in cells).  
The effect of inhibitors on cholesterol efflux was studied by pre-incubating the 
pharmacological agents, BFA (10 µg/mL), Glyburide (500 µM), and BLT-4(150 µM) 
with [3H]-cholesterol labeled cell media for 2 h. After the preincubation, the cells were 
incubated for an additional 5 h at 37°C with the same concentrations of inhibitors in the 
presence or absence of 50 µg/ml lipid-free apoA-I to measure cholesterol efflux. 
Background cholesterol efflux was determined by adding corresponding drug solvents in 
the media containing no acceptors.  Microliter aliquots of the medium were collected at 
specific time intervals to estimate the fraction of [3H]-cholesterol released into the 
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medium by scintillation counting. Following the incubation, the cellular lipids and cell 
culture media were analyzed for radioactivity as described above. 
Western Blots: Aliquots of the cell homogenate of J774.1 (un-stimulated), J774.1 
(stimulated with 8Br-cAMP (300 mM) for 24 h) cells containing 20 µg of protein were 
mixed with reducing SDS-sample buffer and subjected to SDS-PAGE in 8% acrylamide 
gels. The proteins were transferred to a nitrocellulose membrane and probed with a rabbit 
anti mouse/human ABCAI (1:750 dilution). All secondary antibodies were used at a 2500 
fold dilution. The bands were visualized by chemiluminescence. 
ApoA-I cellular Uptake and Re-secretion. Full-length recombinant human apoA-
I was cloned into a pET33b vector (Novagen), which incorporates an N-terminal tag 
encoding for a six-His tag and a five amino acid recognition sequence (RRASV) for the 
catalytic subunit of cAMP-dependent protein kinase (PKA). The protein was expressed in 
E. coli and purified by Ni-affinity chromatography. The activity and specificity of PKA 
against recombinant apoA-I was tested by in vitro phosphorylation with bovine PKA and 
γ-[32P]-ATP. Human apoA-I isolated from serum was not phosphorylated by PKA 
whereas the recombinant protein was highly phosphorylated by PKA.  
In vivo Phosphorylation of apoA-I: J774.1 cells in 12 well dishes were stimulated 
with 8-Br-cAMP and 2 µCi/ml [3H]-cholesterol for 24 h. The cells were then radiolabeled 
by incubation for 4 h with 80 µCi/well of [32P] orthophosphate (carrier free) in 
phosphate-free DMEM media containing 0.12% BSA. At the end of the labeling period, 
300 µM of 8-Br-cAMP was added to the stimulated cells. Recombinant apoA-I (50 µg) 
was also added immediately and cell media was collected at 15, 30, and 60 minutes. The 
collected cell media was loaded into a Ni-affinity column, was washed the column 
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extensively with 20mM imidazole and eluted the recombinant apoA-I with 1M imidazole. 
The eluted proteins were separated by SDS-PAGE on 4-20% gels and subjected to 
autoradiography to visualize the phosphorylation. 
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Results 
Cellular cholesterol efflux to apoA-I 
The rate of cholesterol efflux to apoA-I was studied in J774.1 that were pre-
labeled with [3H]-cholesterol for 24 h. The distribution of radiolabeled cholesterol is 
nearly identical to the relative mass contents of cholesterol suggesting that in 24 h the 
incorporated radiolabeled cholesterol reaches a physiological distribution. It has been 
shown that ABCAI is up-regulated with cyclic AMP analogs in macrophages [113]. In 
this study, we used 300 µM of 8-Br-cAMP to up-regulate ABCAI in J774.1 cells (Fig.18 
A). 
A representative time course of cholesterol efflux to apoA-I (50 µg/mL) is shown 
in figure 18B. The amounts of [3H] cholesterol in the incubation media and the amounts 
remaining associated with the cells were measured, and efflux was expressed as the 
percentage of cellular [3H] cholesterol released into the medium during the 5 h 
incubation. At the concentration of lipoprotein tested (50 µg apoA-I/ml), and after 5 h of 
incubation with un-stimulated and stimulated cells, the total cellular cholesterol efflux is 
approximately 7% and 15% respectively. We observed approximately 30 fold up-
regulation of the total ABCAI protein content in J774.1 cells. 
 
 
 
 
 
 72 
 
 
 
 
0 100 200 300
0
6
12
18 apoA-I
apoA-I+cAMP(24 h)
Time(min)
3 [H
] C
ho
le
st
er
o
l-%
CP
M
 
Fig. 18. Cellular Cholesterol Efflux from J774.1 to Lipid Free apoA-I. A. Western blot showing up-
regulation of ABCAI protein content in J774.1 cells after incubation with 300 µM of8-Br-cAMP for 24 h. 
B. Time course of cholesterol efflux. J774.1 cells were radiolabeled by incubation for 24 h with [3H]-
cholesterol (2 µCi/ml) and 8-Br-cAMP in DMEM containing 2.5% FBS. Cholesterol efflux to apoA-I 
(50µg/mL) was determined at 37 0C in the media of cells that was stimulated with 8-Br-cAMP for 24 h and 
control cells with 8-Br-cAMP added just before the experiment. Samples from three wells were taken at 
different time points. Following the incubation, the cellular lipids and cell culture media were analyzed for 
radioactivity. The mean fraction % of radiolabeled cholesterol detected in the media is shown in the graphs. 
The data plotted is average value of two independent experiments with three replicates ± SD.  
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Effects of inhibitors on ABCAI and SR-BI-mediated cholesterol efflux to apoA-I 
ABCAI and SR-BI are abundantly expressed in macrophages cells. To gain 
quantitative data on the contribution of cholesterol efflux pathways in relation to lipid 
free apoA-I in macrophages, we used 3 inhibitors which are previously shown to inhibit 
receptor mediated (Glyburide, Block Lipid Transfer-4 (BLT-4)) and non-receptor 
mediated pathways (BFA).  BFA, the most extensive studied inhibitor blocks the 
vesicular lipid and protein transport by promoting fusion of Golgi and endoplasmic 
reticulum compartments in the cells [89]. It is reported that Glyburide and BLT-4 blocks 
the ABCAI and apoA-I dependent pathway in cultured cell lines.  
Cholesterol efflux was measured from stimulated (300 µM 8-Br-cAMP) cells 
labeled with [3H] cholesterol for 24 h, followed by a 2 h preincubation with inhibitors. 
This was followed by a 5 h incubation with inhibitors in the presence of 50 µg of protein 
per milliliter of lipid-free apoA-I. The amounts of [3H] cholesterol in the incubation 
media and the amounts remaining associated with the cells were measured, and efflux was 
expressed as the percentage of cellular [3H] cholesterol released into the medium during 
the 5 h incubation.  
Figure 19 shows that the percentages of cholesterol efflux to lipid free apoA-I in 
the presence of inhibitors. The non-receptor mediated BFA (10 g/mL) had a 59% 
inhibition in cholesterol efflux to apoA-I. The ABCAI and SR-BI mediated inhibitors,  
glyburide (500 µM ) and BLT-4 (150 µM) had 92% and 73% inhibition respectively( Fig. 
19). In agreement with earlier studies, our inhibition studies also suggested that lipid free 
apoA-I mediated cholesterol efflux may involve both receptor mediated and non-receptor 
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mediated vesicular transport and ABCAI may play an important role in the lipid free 
apoA-I mediated cholesterol efflux, since glyburide significantly inhibited the pathway.  
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Fig. 19. Effect of Inhibitors on Cellular Cholesterol Efflux from J774.1 to Lipid Free apoA-I.  J774.1 
were labeled with [3H]-cholesterol and then preincubated for 2 h at 37°C in assay medium containing  
DMSO and indicated concentrations of BFA, Glyburide, and BLT-4 . After the preincubation, the cells 
were incubated for an additional 5 h at 37°C with the same concentrations of inhibitors in the presence or 
absence of 50 µg/ml lipid-free apoA-I to measure cholesterol efflux. Following the incubation, the cellular 
lipids and cell culture media were analyzed for radioactivity. The figure represents the percentage 
inhibition of cholesterol efflux to apoA-I. The data plotted is average value of two independent experiments 
with three replicates ± SD) 
 
Uptake and re-secretion of apoA-I by J774.1 macrophage cells 
Several studies reported that the reteroendocytosis of lipoproteins occur in 
macrophages for cholesterol efflux [27, 36-39]. But the retroendocytosis of lipoproteins 
in macrophages or other cell lines are under intense debate because of the ambiguous 
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techniques employed to elucidate this process. In this study we used a novel approach to 
determine the uptake and re-secretion of apoA-I in macrophages. 
A full-length recombinant human apoA-I with an N terminal five amino acid 
recognition sequence (RRASV) for the catalytic subunit of cAMP-dependent protein 
kinase (PKA) was constructed. The protein was expressed in E. coli and purified by Ni-
affinity chromatography. The activity and specificity of PKA against recombinant apoA-I 
was tested by in vitro phosphorylation with bovine PKA and γ-[32P]-ATP. Human apoA-I 
isolated from serum was not phosphorylated by PKA whereas the recombinant protein 
was highly phosphorylated by PKA (Fig. 12).  
 This apoA-I variant allowed studying uptake and re-secretion of apoA-I through 
the appearance of phosphorylated apolipoprotein in the cell culture medium. Because 
protein phosphorylation can only occur intracellularly, the presence of phosphorylated 
apoA-I in the cell medium clearly indicates that the protein was internalized and 
subsequently secreted by the cell. J774.1 stimulated cells (300µM 8-Br-cAMP) cultured 
in 12 well dishes were double radiolabeled by incubation for 4 h with 80 µCi/well of [32P] 
orthophosphate (carrier free) and 2 µCi/ml [3H]-cholesterol for 24 h at 370C in phosphate-
free DMEM containing 0.12% BSA. At the end of the incubation period cell media was 
collected at different time points and loaded into a Ni-affinity column to purify the 
recombinant apoA-I. The eluted proteins were separated by SDS-PAGE on 4-20% and 
subjected to autoradiography to determine the phosphorylation.  
Figure 20 A demonstrates that the rapoA-I is not phosphorylated in the medium of J774.1 
stimulated cells. We have simultaneously tested stimulated J774.1 cells with another 
cAMP analogue, isoproterenol to confirm our results. This also demonstrated absence of 
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phosphorylated apoA-I in the media (data not shown). This suggests that apoA-I does not 
undergo retroendocytossis in macrophages under tested conditions. To further extend out 
studies to other cell lines and evaluate the uptake and re-secretion experiments, we have 
tested retroendocytosis of apoA-I in human liver cells (HepG2 cells). The figure 20B 
shows that the apoA-1 is phoshporylated in a time dependent manner. 
 
 
Fig. 20. Uptake and Re-re-secretion of apoA-I in J774.1 and HepG2 Cells: J774.1 (stimulated) and 
HepG2 cells were radiolabeled by incubation with 4 h at 370C with 80 µCi/ml of [32P]-phosphate in 
phosphate-free DMEM containing 0.12% BSA. Cellular uptake and subsequent re-secretion of apoA-I was 
monitored by incubating the pre-labeled cells with recombinant apoA-I (50µg/ml) containing a 
phosphorylation site for PKA. After incubation for 15, 30 and 60 min with  J774.1 cells and 30 and 60 min 
with HepG2 cells, the cell apoA-I was purified from the cell culture media by Ni-affinity chromatography. 
Proteins were separated by SDS-PAGE on 4-20% gels. A) The apoA-I region of the Coomassie Blue-
stained gel (upper) and the corresponding autoradiogram (lower) of J774.4 cells. B). The apoA-I region of 
the Coomassie Blue-stained gel (upper) and the corresponding autoradiogram (lower) of HepG2 cells. 
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Discussion 
HDL and apoA-1 stimulate cholesterol efflux from macrophage foam cells and 
reduce cholesterol accumulation and atherogenesis in mouse models [110-112]. It is very 
important to understand the apoA-I cholesterol efflux pathways, because of its prime role 
in the biogenesis of HDL. ABCAI and SR-BI are the two known cell receptor proteins 
that mediate apoA-I and HDL cholesterol efflux. The lipoproteins and receptors play an 
important role in cholesterol metabolism in mammalian systems and abnormality in these 
components are correlated with far-reaching pathologies [31, 105].  
As shown previously, our studies also confirmed that apoA-I efficiently efflux 
cholesterol from macrophages. The apoA-I induced cholesterol efflux is approximately 
15% of the total cellular cholesterol. Our previous study has shown that adipose tissue 
cholesterol efflux to apoA-1 is approximately 1.8% of the total cellular cholesterol. This 
result illustrates the difference in the characteristic properties of peripheral cells in 
relation to apolipoprotein induced cholesterol efflux. Considering the total cellular 
cholesterol present in the adipose tissue, the 1.8% cholesterol efflux is significant. But the 
difference in the percentage efflux of the total cellular cholesterol is the individual 
characteristic property of peripheral cells. Also it is confirmed that the pharmacological 
drugs like BFA, glyburide and BLT-4 have significant effect on the global cholesterol 
efflux pathways. The inhibition of ABCAI and SR-BI receptors and vesicular transport 
by the drugs suggested that apoA-I induce cholesterol efflux through multiple pathways 
in J774.1 cells. These cholesterol efflux pathways could be activated through vesicular 
transport (with and without the involvement of receptors), ABCAI, SR-BI, ABCGI and 
other unidentified pathways and receptors.  
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Several studies reported that the reteroendocytosis of lipoproteins occur in 
macrophages for cholesterol efflux [27, 36-39]. But the retroendocytosis of lipoproteins 
in macrophages or other cell lines are under intense debate because of the ambiguous 
techniques employed to elucidate this process.  
To investigate the possibility of up-take and re-secretion of apoA-I in macrophage 
cells, we used a novel approach in which a full-length recombinant human apoA-I with 
an N terminal five amino acid recognition sequence (RRASV) for the catalytic subunit of 
cAMP-dependent protein kinase (PKA) was constructed. Because the protein 
phosphorylation can only occur intracellularly, the presence of phosphorylated apoA-I in 
the cell medium clearly indicates that the protein was internalized and subsequently 
secreted by the cell. The constructed recombinant protein was further tested for their 
phosphorylation in vitro abilty.  
Our studies unambiguously showed that adipose and HepG2 cells uptake and re-
secrete lipidated apoA-I in time specific manner. But with the same approach and with 
two different cAMP stimulating drugs, apoA-I did not undergo retroendocytosis in J774.1 
cells.   This result is in opposite to the proposed hypothesis of apoA-I retroendocytosis in 
macrophages published from several labs. The result suggests that cells do not prefer 
some cholesterol efflux pathways and have specific routes of intracellular lipid traffic to 
PM for the availability for the external acceptors. It is important to note here that shortly 
after the first paper on retroendocytosis of HDL, another study observed absence of 
internalization of (125I) HDL in fibroblast and macrophages[40]. Further the authors 
suggested that in macrophages, HDL stimulate the transport of lipids from intercellular 
locations to cell surface, rather than undergoing retroendocytosis [40, 41]. 
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CHAPTER V 
Summary 
The current studies are important to understand the reverse cholesterol transport 
(RCT) in vertebrates. Reverse cholesterol transport is the process by which excess 
unesterified cholesterol is transported from peripheral tissues to the liver for excretion 
from the body. Several lines of evidence suggest that defects in RCT contribute to the 
development of atherosclerosis. Adipose tissue constitutes a major site of cholesterol 
storage and, as such, it may play a role in the regulation of circulating cholesterol levels. 
The understanding of metabolic link between the lipolytic state (hydrolysis of 
triacyglycerol) of adipocytes and the mechanism of release of cellular cholesterol to 
external cholesterol acceptors like apolipoproteinA-I (apoA-I) and high density 
lipoprotein (HDL) is necessary to elucidate the role of adipose tissue in whole body 
cholesterol homeostasis. 
Our study shows that β-adrenergic activation of the lipolysis significantly 
increases the extent of cholesterol efflux to reconstituted discoidal HDL particles.  The 
enhancement of cholesterol efflux is not due to the enrichment of plasma membrane 
cholesterol, or to the levels of the cholesterol transporters ABCAI and SR-BI. The 
activation of lipolysis is accompanied by an increase in BFA-sensitive vesicular transport 
that in turn enhances cholesterol efflux to HDL. The study supports a metabolic link 
between the lipolytic activity of adipocytes and the rate of cellular cholesterol efflux to 
HDL.  
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The activation of lipolysis does not induce a significant increase in the rate of 
cholesterol efflux to lipid free apoA-I. The known vesicular and non-vesicular cholesterol 
efflux inhibitors inhibit global cholesterol efflux significantly. We have evidently 
presented that lipid free apoA-I undergo retroendocytosis in mouse adipose tissue, human 
liver cells but not in human macrophages. The known cholesterol efflux inhibitory drugs 
had no effect on the uptake and recycling of apoA-I.  
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APPENDIX 
ABCAI and SR-BI siRNA adenovirus construction and testing 
 
Introduction 
Reverse cholesterol transport (RCT) is the process by which excess unesterified 
cholesterol is transported from peripheral tissues to the liver for excretion from the body 
[9, 10]. The FC efflux is one of the decisive early steps of the RCT and high-density 
lipoprotein (HDL) and apoA-I serve as the main acceptors for the cellular cholesterol 
released from the peripheral cells [11]. The current data indicate that apoA-I interact with 
ABCAI receptor for the initial lipidation and further through several intermediate steps 
form the discoidal and mature HDL molecules. The discoidal and mature HDL molecules 
interact with SR-BI receptor of peripheral cells to acquire excess lipids and further 
deliver to liver. ABCAI and SR-BI are considered as important receptors in the 
biogenesis of HDL and whole body cholesterol homeostasis. It is important to study the 
role of these receptors in different peripheral tissues. In order to quantitatively determine 
the efflux capacities of ABCAI and SR-BI receptors, we decided to prepare adenoviral 
siRNA for these receptors. Our objective was to prepare adenovirus containing 
interfering RNA to silence the ABCAI and SR-BI receptors.  
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ABCAI and SR-BI siRNA adenovirus construction and testing 
Small interference (si) RNA synthesis and transfection: For ABCAI RNA 
inhibition, siRNA 5’AACAGGTTTGGAGATGGTTAT 3’ was designed from the full-
length mouse ABCAI sequence corresponding to position 6717-6737 of NM_01345 
(Genbank accession number). For SR-BI RNA inhibition, siRNA  
5’AAGCAGCAGGTGCTCAAGAAT 3’ was designed from the full-length mouse SR-BI 
sequence corresponding to position 301- 321of NM_016741 (Genbank accession 
number) respectively. The specificity to the targeted genes were confirmed by searching 
the targeting segments with NCBI blast.  
The sense and antisense DNA oligonucleotides that encode the hairpin siRNA 
template (55-mer oligonucleotide) were synthesized commercially by Integrated DNA 
Technologies (Coralville, IA). The oligos were annealed to form the siRNA template 
were inserted and ligated into the Shuttle Vector 1.0 CMV (pSilencer adeno 1.0 CMV 
system, Ambion, Catalog # 5790). The Negative Control Shuttle Vector supplied with the 
kit that contains a siRNA template sequence that lacks significant homology to the 
mouse, human, and rat genome databases can serve as a negative control. 
The linearized Shuttle Vector containing the siRNA template and the linearized 
Adenoviral LacZ Backbone plasmid were mixed and transfected in HEK-293 (kidney) 
cells by calcium phosphate method according to the manufacturer’s protocol (Ambion, 
Catalog # 5790). Recombination of the two plasmids within the HEK-293 cells resulted 
in the production of recombinant adenovirus.  
A titration experiment was done to optimize the amount of recombinant 
adenovirus for the best expression of the hairpin siRNA. HEK 293 cells were infected 
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with dilutions of the viral stock and after 48 hours, the cells were fixed and stained with 
the antibody specific for the adenovirus hexon protein. Signal was detected with a 
secondary antibody conjugated with horseradish peroxidase (HRP) specific to the 
antihexon antibody. Subsequent treatment of the cells with DAB substrate turned the 
infected cells to dark brown,which were counted to determine the virus titer. (Adeno-X 
Rapid Titer Kit, Clontech). Figure 21 shows different dilutions of the HEK 293 cells 
infected with ABCAI adenovirus. 
 
 
 
 
 
 
3T3L-1 and J774.1 cells in 12 well plates were incubated with 10-2 dilution of 
adenovirus containing ABCAI siRNA for 24 h, 48 h and 72 h. After the incubation, cells 
Fig. 21. Dilutions of the HEK 293 cells infected with ABCAI adenovirus 
as indicated. The photos were taken using a 10X objective. 
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were homogenized and aliquots of the homogenate containing 20 µg of protein were 
mixed with reducing SDS-sample buffer and subjected to SDS-PAGE on 8% acrylamide 
gels. The proteins were transferred to a nitrocellulose membrane and probed with a rabbit 
anti-mouse/human ABCAI (1:750 dilutions). The bands were visualized by 
chemiluminescence. Fig. 22 shows the representative western blot result of J774.1 cell 
homogenate. Results showed no changes in the level of ABCAI protein under the 
conditions tested. Further tests are required to optimize the conditions and titer of the 
virus.  
 
 
 
Fig. 22. ABCAI Protein Levels after the Treatment of ABCAI siRNA Containing Adenovirus in 
J774.1 cells. A) Western blotting of ABCAI performed in homogenate samples (20 µg of protein/sample) 
after SDS-PAGE. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
ABCAI 
Time 
 Adenovirus - + 
72 h 48 h 
+ - 
  
VITA 
 
Philip Benjamin Verghese 
 
Candidate for the Degree of 
 
Doctor of Philosophy 
 
 
Thesis:    CHOLESTEROL EFFLUX IN ADIPOSE TISSUE 
 
 
Major Field:  Biochemistry & Molecular Biology 
 
 
Education:   
BSc. in Chemistry, University of Pune, Pune, India. 1992-1995 
 
MSc. in Biochemistry, University of Pune, Pune, India. 1995-1997 
 
Graduate Diploma in Business Studies (GDBS), Dublin Business School, Dublin, Ireland. 
2000-2001 
 
Completed the requirements for the Doctor of Philosophy in Biochemistry and Molecular 
Biology at Oklahoma State University, Stillwater, Oklahoma in December, 2007. 
 
Experience:   
Graduate Research Associate, Department of Biochemistry & Molecular Biology, 
Oklahoma State University, Stillwater, OK. 2001-Present 
 
Research Fellow, Sree Chitra Tirunal Institute for Medical Sciences & Technology, 
Kerala, India.1997-1998 
 
Professional Memberships:   
 
  American Association for the Advancement of Science 
 ADVISER’S APPROVAL:   Jose L. Soulages 
 
Name: Philip Benjamin Verghese                          Date of Degree: December, 2007 
 
Institution: Oklahoma State University                  Location: Stillwater, Oklahoma 
 
Title of Study: CHOLESTEROL EFFLUX IN ADIPOSE TISSUE 
 
Pages in Study: 93                Candidate for the Degree of Doctor of Philosophy 
Major Field: Biochemistry & Molecular Biology 
 
Scope and Method of Study:  
The current studies are important to understand the reverse cholesterol transport (RCT) in 
vertebrates. Reverse cholesterol transport is the process by which excess unesterified 
cholesterol is transported from peripheral tissues to the liver for excretion from the body. 
Several lines of evidence suggest that defects in RCT contribute to the development of 
atherosclerosis. Adipose tissue constitutes a major site of cholesterol storage and it may 
play a role in the regulation of circulating cholesterol levels. The understanding of 
metabolic link between the lipolytic state (hydrolysis of triacyglycerol) of adipocytes and 
the mechanism of release of cellular cholesterol to external cholesterol acceptors like 
apolipoproteinA-I (apoA-I) and high density lipoprotein (HDL) is necessary to elucidate 
the role of adipose tissue in whole body cholesterol homeostasis. 
 
 
Findings and Conclusions:  
 Our study shows that β-adrenergic activation of the lipolysis significantly increases the 
extent of cholesterol efflux to reconstituted discoidal HDL particles.  The enhancement of 
cholesterol efflux is not due to the enrichment of plasma membrane cholesterol, or to the 
levels of the cholesterol transporters ABCA1 and SR-BI. The activation of lipolysis is 
accompanied by an increase in BFA-sensitive vesicular transport that in turn enhances 
cholesterol efflux to HDL. The study supports a metabolic link between the lipolytic 
activity of adipocytes and the rate of cellular cholesterol efflux to HDL. The activation of 
lipolysis does not induce a significant increase in the rate of cholesterol efflux to lipid 
free apoA-I. The known vesicular and non-vesicular cholesterol efflux inhibitors inhibit 
global cholesterol efflux significantly, but not specific cholesterol efflux to apoA-I. We 
have evidently presented that lipid free apoA-I undergo retroendocytosis in mouse 
adipose cells, human liver cells but not in human macrophage cells. The known 
cholesterol efflux inhibitory drugs had no effect on the uptake and recycling of apoA-I.  
 
 
 
 
 
 
 
 
